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ABSTRACT

USE OF NOVEL ASSAYS TO MEASURE IN VIVO BASE EXCISION DNA REPAIR
by Preethi Sundaresakumar

Oxidative DNA damage due to reactive oxygen species (ROS) can cause
single-base alterations such as 8-oxo-7,8-dihydroguanine (8oxodG) lesions, which are
repaired by the base excision DNA repair (BER) pathway. Assays developed to date, to
measure BER, are limited by in vitro analysis and use of radiolabeled reagents. This
thesis outlines the design of a novel assay to measure the kinetics of BER in vivo, using a
biotin-tagged oligonucleotide DNA substrate that contains an 8oxodG lesion. The
substrate DNA is transfected into target cells and incubated to allow repair of the lesions.
The DNA is then captured following cell lysis and the disappearance of 8oxodG lesions
is monitored using competitive 8oxodG ELISA. This assay was developed to corroborate
the results obtained from our investigations on the role of the breast cancer susceptibility
protein-1 (BRCA1) in BER, using another novel in vivo assay called the host-cell
reactivation (HCR) assay. Preliminary results from this study showed that BRCA1 is
involved in BER. Together, these in vivo assays may be used to identify potential cancer
genes that regulate the BER pathway.
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INTRODUCTION

Cellular DNA constantly faces assault from various endogenous and exogenous
agents. Nucleotides are oxidized on exposure to reactive oxygen species (ROS) which
are generated endogenously during various cellular metabolic processes (Friedberg et al.,
2006a, chap. 2). Oxidized guanine products such as 8-oxo-7,8-dihydroguanine (8oxodG)
are common ROS-induced single base alterations. Unless repaired, oxidative DNA
damage results in genetic instability and tumorigenesis. The base excision DNA repair
(BER) pathway is the major cellular pathway that corrects oxidation-induced single base
alterations (David, O'Shea, & Kundu, 2007; Dizdaroglu, 2005; Mitra, Boldogh, Izumi, &
Hazra, 2001; Seeberg, Eide, & BJ0ras, 1995).
A number of assays have been developed to monitor BER activity. These assays
have been used to identify the various steps and the proteins involved in the pathway. In
addition, they allow comparison of repair activity in different cell types following
exposure to oxidative stress. However, such assays are limited due to the need for in
vitro analyses using cell extracts and the use of radiolabeled reagents.
In this study, we have designed a novel assay to measure BER of 8oxodG lesions
in vivo, and optimized the working conditions for some of the steps in the assay. This
assay measures the repair of a short double-stranded oligonucleotide DNA substrate
carrying a single 8oxodG lesion on one strand and a 3' biotin tag on the complementary
strand. Following transfection of the substrate DNA into target cells and incubation to
allow time for repair, the cells are lysed, and the biotin-tagged substrate DNA is captured
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using streptavidin-coated magnetic beads. The 8oxodG lesions on the substrate DNA are
then quantified using a competitive 8oxodG enzyme-linked immunosorbent assay
(ELISA). The amount of 8oxodG lesions quantified is inversely proportional to the
efficiency of BER in the cells.
The in vivo BER assay was designed to corroborate the preliminary results
obtained from another study conducted as part of this thesis. This study involved the
investigation of the role of the breast cancer susceptibility protein-1 (BRCA1) in the BER
pathway, using a novel host-cell reactivation assay (HCR) for BER that was recently
developed in our laboratory. This assay for BER monitors the ability of cells in culture to
remove transcription-blocking 8oxodG lesions introduced ex-vivo into a green fluorescent
protein (GFP) reporter gene in a recombinant adenovirus. Repair of the 8oxodG lesions
by the cellular BER pathway allows for expression of GFP, which can be measured using
standard fluorescence detection methods. In our study, a wild-type BRCA1 expression
vector was transfected into BRCA1 deficient cells, and the cells were subjected to the
HCR assay. Preliminary results show that the BRCA1 protein enhances the BER
pathway.
This thesis has been divided into two chapters. In the first chapter, the
preliminary investigations on the role of the BRCA1 protein in BER using the HCR assay
have been described. In the second chapter, the development of a novel assay to measure
the in vivo BER of 8oxodG lesions has been described. In the following section, an
overview of oxidative DNA damage, 8oxodG lesions, and the BER pathway has been
provided, to serve as an introduction to the two chapters that follow.
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Oxidative DNA Damage
Cellular DNA is susceptible to oxidation by ROS and transition metals (Neely &
Essigmann, 2006). In the cell, ROS are by-products of aerobic metabolism. They are
also generated during metabolism of xenobiotic compounds (Park et al., 2005) and
phagocytosis (Bogdan, Rollinghoff, & Diefenbach, 2000). ROS may also be introduced
exogenously by radiation, redox cycling compounds, drugs, or cigarette smoke
(Friedberg et al., 2006a, chap. 2). Different types of ROS include superoxide (O2 ),
hydroxyl (OH), peroxyl (R0 2 ), alkoxyl (RO), hydroperoxyl (HO2 ), singlet oxygen
(]02), peroxynitrite (ONOO), and hydrogen peroxide (H2O2). A cell usually decreases
ROS levels using free radical scavengers and antioxidant enzymes (Pacifici & Davies,
1991). When these defenses fail, elevated ROS levels cause damage to nucleic acids,
proteins, carbohydrates, and lipids in a cell (Friedberg et al., 2006a, chap. 2).
ROS induce the formation of a plethora of DNA oxidation products (Bjelland &
Seeberg, 2003), some of which are 8oxodG, thymine glycol, formaminopyrimidine, and
5-hydroxycytosine. It is usually the electrophilic carbon centers of the bases that are
oxidized (Nilsen & Kroken, 2001). If left unrepaired, oxidized bases lead to
apurinic/apyrimidic (AP) sites and strand breaks (Friedberg et al., 2006a, chap. 2), and
result in DNA mutations, genetic instability, and cancer. Oxidized bases and AP sites are
mainly repaired using the BER pathway (Seeberg et al, 1995). Some oxidative lesions
also appear to be repaired by the nucleotide excision repair (NER) and mismatch repair
(MMR) pathways (Bjelland & Seeberg, 2003). Strand breaks may be repaired by
homologous recombination (HR) or non-homologous end-joining (NHEJ) mechanisms.
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8-oxo- 7,8-dihydroguanine (8oxodG)
Among the ROS-induced DNA oxidation products, guanine oxidation products
occur most frequently. This is because guanine, owing to its low reduction potential
(Ej = 1.29 V) (Neely & Essigmann, 2006; Steenken & Jovanovic, 1997), is more
susceptible to oxidation (Bjelland & Seeberg, 2003). A guanine oxidation product that
has been thoroughly examined and is often used as a biomarker of cellular oxidative
stress is 8oxodG (David et al., 2007) (Figure 1).

H,N
DNA

Figure 1. Chemical formula of 8-oxo-7,8-dihydroguanine.

8oxodG lesions are highly stable and mutagenic. Their stability is evidenced by
the fact that these lesions were detected among eight oxidative base modifications in
ancient DNA (Hoss, Jaruga, Zastawny, Dizdaroglu, & Paabo, 1996). In the anti
conformation, they form 8oxodG {anti) - C {anti) base pair. However, in the syn
conformation, they mimic thymidine and thus form a stable 8oxodG {syn) - A {anti) base
pair (David et al., 2007). Such base pairing specificities allow bypass of 8oxodG lesions
by replicative DNA polymerases (Shibutani, Takeshita, & Grollman, 1991) and this
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ultimately results in GC to TA transversion mutations (Cheng, Cahill, Kasai, Nishimura,
& Loeb, 1992). In humans, a set of three enzymes (called the GO system) are involved in
the repair of 8oxodG lesions. The enzyme MutT homolog 1 (MTH1) hydrolyzes
8oxodGTP bases from the nucleotide pool, thereby preventing their incorporation into
DNA. The human 8-hydroxyguanine DNA glycosylase (hOGGl), functions in the first
step of the BER pathway to specifically detect and excise the 8oxodG lesion from the
8oxodG-C base pair. If 8oxodG is not removed by hOGGl, then following replication,
the 8oxodG base pairs with adenine. The enzyme MutY homolog (MUTYH) then
removes the adenine from the 8oxodG-A base pair, and allows the incorporation of a
cytosine opposite the 8oxodG base. This provides another opportunity for the hOGGl
enzyme to excise the 8oxodG lesion (Friedberg et al., 2006b, chap. 6).

Base Excision DNA Repair (BER)
To deal with the constant assaults faced by cellular DNA, repair pathways have
evolved, each specializing in the correction of certain types of damage. The BER
pathway, first discovered by Tomas Lindahl in 1974, specializes in the repair of small
base alterations that do not distort the DNA helix (Fromme & Verdine, 2004). Besides
oxidized bases, the BER pathway also recognizes and repairs alkylated bases (formed due
to base exposure to S-adenosylmethionine and tobacco-specific nitosamines), AP sites
(formed by the spontaneous loss of purines from DNA) and deaminated bases (resulting
from hydrolytic deamination of amine-containing DNA bases) (Fromme & Verdine,
2004).
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The BER system consists of a group of lesion-specific enzymes termed DNA
glycosylases, which recognize and excise specific base modifications, resulting in AP
sites. Other enzymes act in a series of steps to fill in the missing base, and ultimately
restore the correct sequence (Krokan, Nilsen, Skorpen, Otterlei, & Slupphaug, 2000).
Since the focus of this thesis is on the repair of oxidized bases (particularly 8oxodG), a
brief description of the steps involved in the BER of 8oxodG lesions is given below.
The hOGGl glycosylase is the mammalian DNA glycosylase that recognizes and
excises the 8oxodG lesion from 8oxodG-C base pairs. The enzyme removes 8oxodG
lesions via displacement using a nucleophile active-site residue, which is an amine
(Fromme & Verdine, 2004). Following displacement of 8oxodG, hOGGl catalyses the
cleavage of the N-glycosyl bond between the lesion and deoxyribose in the backbone,
resulting in an AP site. Being a bifunctional DNA glycosylase, hOGGl has both DNA
glycosylase and DNA lyase activities. Thus, following removal of the 8oxodG lesion, the
lyase activity allows the enzyme to cleave the DNA backbone on the 3' side of the lesion
resulting in the generation of a 3'-a, P-unsaturated aldehyde end and a 5' phosphate end.
The human apurinic/apyrimidic endonuclease 1 (APE1) then removes the
3'-a, |3-unsaturated aldehyde by virtue of its 3'- phosphodiesterase activity. This results in
a single nucleotide gap that is flanked by 3' hydroxyl and 5' phosphate ends. DNA
polymerase P then fills the gap and the strand is resealed by DNA ligase III and X-ray
Repair Complementing Defective Repair in Chinese Hamster Cells 1 (XRCC1)
heterodimers (Figure 2A) (Friedberg et al., 2006b, chap. 6; Fromme & Verdine, 2004;
Hirano, 2008).
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Studies have shown that in the presence of APE 1, the hOGGl lyase activity is
bypassed (Vidal, Hickson, Boiteux, & Radicella, 2001). APE1 then directly cleaves the
backbone at the 5' side of the AP site resulting in the formation of a 3' hydroxyl end and a
5' deoxyribose phosphate (dRP) end. Beyond this step, repair can proceed in one of two
alternative pathways which involve either the replacement of one (short-patch BER) or
more nucleotides (long-patch BER) at the lesion site (Fortini et al., 2003). It has been
shown that hOGGl-mediated repair of 8oxodG occurs almost exclusively along the
short-patch pathway (Fortini, Parlanti, Sidorkina, Laval, & Dogliotti, 1999). In
short-patch BER (SP-BER), following cleavage by APE1, DNA polymerase P removes
the 5'-dRP due to its intrinsic dRPase activity and then fills in the gap due to its DNA
polymerase activity. The strand is then resealed by DNA ligase III and XRCC1
heterodimers, or DNA ligase I (Figure 2B) (Friedberg et al., 2006b, chap. 6; Fromme &
Verdine, 2004).

7

3"

~0"
_£j

3'-

g'

hOGG1 (DNA glycosylase activity)
A

APE-1

hOGGI (DNA lyase activity)
"N,

3

* p-Q

^-

5

._L

C

G_

:

5

.,

3'—L.

£"~" dRP"

Polp (elRPase activity)

APE-l

d

—7T

3'

5—jfH

-OH

3-

L-

I

^~c
C

G

3'
5=

/

\
Poip (DNA polymerase activity)

Poip (DNA polymerase activity)

XRCC1
DNA, Liaase 3a

C

n

XRCC1

IT

DNA Ligase 3a

Figure 2.. Base excision repair of 8oxodG lesions in mammalian cells. The hOGGI
enzyme excises the 8oxodG base (O) in an 8oxodG-C base pair, resulting in an AP site.
Using its lyase activity (A), the enzyme then cleaves the DNA backbone on the 3' side of
the lesion resulting in the generation of a 3'-a, [3-unsaturated aldehyde end (*) and a 5'
phosphate (P) end. The APE1 enzyme then removes the 3'-a, P-unsaturated aldehyde,
thereby creating a single nucleotide gap that is flanked by 3' hydroxyl (OH) and 5'
phosphate (P) ends. DNA polymerase P (Pol P) then fills the gap and the strand is
resealed by a DNA ligase III/XRCC1 heterodimer. Alternatively (B), the hOGGI lyase
activity is bypassed and following 8oxodG base excision, APE1 directly cleaves the
backbone at the 5' side of the AP site resulting in the formation of a 3' hydroxyl end (OH)
and a 5' deoxyribose phosphate (dRP) end. Following cleavage by APE1, Pol p removes
the 5'-dRP, and then fills in the single nucleotide gap. The strand is then resealed by the
DNA ligase III and XRCC1 heterodimer or DNA ligase I.
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CHAPTER ONE

INVESTIGATION ON THE ROLE OF BRCA1 IN BER USING
THE HOST-CELL REACTIVATION ASSAY

Introduction

The Breast Cancer Susceptibility Gene-1 (BRCA1)
The BRCA1 gene was mapped to chromosome 17q21 by Miki et al. in 1994. It
contains 24 exons that encode a 220 kDa protein of 1863 amino acids. The protein
consists of multiple functional domains; a highly conserved N-terminal Really Interesting
New Gene-1 (RING) finger domain (residues 1-112), two centrally located
nuclear-localization signals (NLS), an 'SQ' cluster domain (SCD) containing serine and
glutamine residues (residues 1280-1524), and two BRCA1 carboxy terminal (BRCT)
domains (residues 1646-1863) (Deng, 2006; Venkitaraman, 2001).
The BRCA1 protein functions as a tumor suppressor and has been implicated in a
number of cellular activities such as cell cycle checkpoint control, centrosome
duplication, chromatic remodeling and transcription, replication, recombination, DNA
repair, ubiquitination and apoptosis (reviewed in Daniel, 2002; Deng, 2006; Scully, Xie,
& Nagaraju, 2004; Starita & Parvin, 2003; Venkitaraman, 2001; Yarden & Papa, 2006).
Deng (2006) proposed that a loss of these functions may be responsible for the gross
genetic instability observed in BRCA1 -mutated mouse and human mammary tumors
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(Weaver et al., 2002; Xu et al, 1999). A study (Tirkkonen et al., 1997) also showed that
BRCA1 -associated breast cancers have high levels of chromosomal aneuploidy when
compared to breast carcinomas lacking a BRCA1 mutation. While on one hand, this
genetic instability triggers DNA damage response pathways leading to growth arrest and
activation of pro-apoptotic signals, on the other hand, the cell continues to accumulate
mutations in critical tumor regulatory genes, including p53, PTEN, Rbl, ErbB2, c-Myc,
p27, and cyclin Dl, that initiate carcinogenesis (Brodie et al., 2001; Deng, 2006; Xu et
al., 1999).

BRCA1-Associated Breast Cancers
Breast cancer is the second leading cause of cancer mortality in Western women
(Deng, 2006). About 10% of breast cancer cases are heritable; the remaining being
sporadic cases (Easton & Peto, 1990). Approximately 50% of heritable breast cancer
cases and 80% of combined breast and ovarian cancer cases occur due to mutations in
BRCA1 (Yarden & Papa, 2006). More than 90% of the identified germ-line BRCA1
mutations introduce premature termination codons into the BRCA1 coding sequence;
most of the truncated BRCA1 mRNA transcripts are degraded by the nonsense-mediated
mRNA decay pathway (Perrin-Vidoz, Sinilnikova, Stoppa-Lyonnet, Lenoir, & Mazoyer,
2002). Thus, the level of BRCA1 truncated proteins expressed (if any) is very low.
Among sporadic cases of BRCA 1 -associated breast cancer, epigenetic silencing of
BRCA1 in the form of promoter hypermethylation rather than BRCA1 mutations is
commonly seen (Catteau & Morris, 2002). This results in the loss of BRCA 1 gene
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expression. A few studies have also attributed the low expression ofBRCAl in sporadic
breast cancers to the degradation of BRCA1 proteins (Blagosklonny et al., 1999) and/or
transcriptional repression of the BRCA1 gene (Budhram-Mahadeo, Ndisang, Ward,
Weber & Latchman, 1999).

BRCA1 and Base Excision DNA Repair
As mentioned previously (in the "Introduction" section of this thesis), several
endogenous and exogenous factors are responsible for cellular oxidative stress. In
addition to those factors, a breast-specific mechanism is also responsible for oxidative
stress in breast tissues: the accumulation of hydrogen peroxide following the metabolism
of 17(3-estradiol by lactoperoxidase (Sipe, Jordan, Hanna, & Mason, 1994). Under these
conditions, if the cellular antioxidant defense systems and/or DNA repair systems are
compromised, the DNA begins to rapidly accumulate oxidative damage, resulting in
genetic instability and initiation of breast carcinoma (Malins & Haimanot, 1991).
Previous studies in our laboratory (Alii, 2008) showed that mouse mammary
epithelial cells deficient in BRCA1 had higher levels of oxidative DNA damage (oxidized
bases were measured using the comet assay) when compared to cells containing the
wild-type BRCA1. In addition, BRCA1 -mutated breast cancer cell lines (SUM149PT,
SUM1315M02, HCC1937, and MDAMB436) were found to be more sensitive to
treatment with hydrogen peroxide when compared to normal (but immortalized) breast
cell lines (MCF10A and MCF12A) (Alii, 2008). Since BER is the major pathway that
repairs oxidative DNA damage, and a direct correlation between resistance to oxidative

11

DNA damage and cellular BRCA1 levels was seen in previous studies, we decided to
investigate if BRCA1 was involved in the BER pathway.
In this study, we hypothesized that the BRCA1 protein plays a role in BER, and
so breast tissue with low BRCA1 expression or with a mutant BRCA1 has defective BER,
and thus increased oxidative DNA damage. This may then result in genetic instability
leading to the initiation and progression of breast carcinogenesis. For our study, we used
the SUM149PT breast cancer cell line. This is an adherent, ductal epithelial cell line that
originated from the inflammatory breast carcinoma of a 35 year old patient (Elstrodt et
al., 2006). The genome copy number aberrations and gene expression profile of this cell
line has been previously studied (Neve et al., 2006). SUM149PT cells have a deletion
(2288delT) in exon 11 of the BRCA1 coding region, which results in a premature
termination codon (Elstrodt et al., 2006) in the mRNA transcript. Semiquantitative
RT-PCR analysis has previously confirmed the presence of very low levels (Elstrodt et
al., 2006) or complete absence (Alii, 2008) of BRCA1 mRNA transcripts in these cells,
which could be due to the nonsense-mediated decay of the truncating transcripts. This is
also consistent with previous results obtained following Western blot analysis (Alii,
2008; Elstrodt et al., 2006) and immuno-histochemistry (Elstrodt et al., 2006) on paraffin
embedded cells, which showed the complete absence of BRCA1 proteins in the nucleus
of SUM149PT cells. To test our hypothesis, a constitutive wild-type BRCA1 expression
plasmid was transfected into the SUM149PT cells. Cells transfected with the empty
vector alone were used as a negative control. The transfected cells were then subjected to
a novel host-cell reactivation assay (HCR) to measure in vivo BER activity.
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Materials and Methods

Cell Lines and Media
SUM149PT cells (Asterand) were cultured in Ham's F12 media (Gibco)
supplemented with 10% (vol/vol) fetal bovine serum (FBS) (Gibco), IX
penicillin/streptomycin/fungizone (P/S/F) (Mediatech Inc.), 5 |J.g/ml insulin (Sigma
Aldrich), 1 ug/ml hydrocortisone (Sigma Aldrich) and 10 mM HEPES (Gibco). Their
morphology, growth rate, and lack of BRCA1 gene expression was regularly monitored in
our laboratory (using RT-PCR and Western blotting). The earliest passages of the cell
line were used for our experiments. MCF7 cells were cultured in media containing
DMEM (Mediatech Inc), 10% FBS and IX P/S/F. All the cells were maintained in
5% CO2 at 37 °C. The cells were frozen in media containing 10% (vol/vol) DMSO.

Confirmation of the Wild-Type BRCA1 Construct and the Empty Vector Control
The wild-type BRCA1 expression plasmid (pcDNA3fi-BRCAl) and the empty
vector control (pcDNA3) were kindly provided by Dr. Simon Powell (Washington
University, St. Louis). The constructs were transformed into the OneShot® TOP 10
chemically competent E.coli cells (Invitrogen) according to the manufacturer's
instructions. Each transformation mix was then plated on LB agar plates containing
100 |j,g/ml ampicillin (Sigma Aldrich), and the plates were inverted, and incubated at
37 °C overnight. Single, well-isolated colonies were picked and grown overnight in
sterile snap-capped polystyrene tubes containing 3 ml of LB/ampicilin (100 ug/ml) media
at 37 °C, 250 rpm. Plasmids were isolated from 2 ml of each cell suspension using the
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GenElute™ Plasmid Miniprep Kit (Sigma Aldrich), and their DNA concentration was
estimated using UV-Vis spectrophotometry (BioPhotometer, Eppendorf). The remaining
cell suspension was stored at 4 °C to prepare frozen glycerol stocks, once the positive
clones were identified following restriction analysis.
If restriction analysis was not performed on the same day that the plasmids were
isolated, then prior to plasmid isolation, cell suspensions from each sample were spotted
on a grid-plate containing LB agar with 100 fig/ml ampicillin, and labeled. The plates
were sealed and stored at 4 °C. Following identification of positive clones, cell
suspensions were prepared from the corresponding grids as described before.
For the restriction analysis of the pcDNA3P-i?i?C47 construct, unique restriction
sites on the pcDNA3 vector backbone (Invitrogen) and the BRCA1 coding sequence
(Genbank accession number NM_007294) were identified using Webcutter 2.0
(developed by Heiman, 1997). Two restriction sites {Nhel, Xhol) on the
pcDNA3 fi-BRCAl construct which on cutting would yield restriction fragments of
unequal sizes, that would be easily detectable following gel analysis, were chosen. The
pcDNA3 constructs were digested using the restriction enzyme Pstl, as suggested by the
manufacturer.
Plasmids (2.5 \ig) isolated from the pcDNA3fi-BRCAl transformed clones were
digested at 37 °C for 2 hr with Nhel (30 U) (Gibco BRL) in React 4 buffer (Gibco BRL),
followed by digestion at 37 °C for 1 hr withZfcoI (20 U) (NEB) in NEB 2 buffer (NEB).
Plasmids obtained from pcDNA3 transformed clones were digested with Pstl (30 U)
(NEB) at 37 °C for 3 hr. A final concentration of 100 (ig/ml of bovine serum albumin
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(BSA) (NEB) was included in the Pstl restriction digest. The restricted plasmids were
electrophoresed on a 1% agarose gel (containing 3 ug of ethidium bromide per ml of
molten agarose) in Tris acetate EDTA (TAE) buffer, along with a 1 kb DNA ladder
(Invitrogen). The DNA fragments on the gel were visualized using 300 nm UV
illumination (Chemilmager 4400, Alpha Innotech).

Large Scale Amplification of the Wild-Type BRCA1 Construct and Empty Vector Control
for Use in Transfection
Prior to transfection, a small amount of frozen culture from the pcDNA3$-BRCAl
and pcDNA3 glycerol stocks was removed and streaked on LB agar plates with
100 iag/ml ampicillin and incubated overnight at 37 °C. A single colony was removed
and suspended in sterile snap-cap polystyrene tubes containing 2 ml of LB/ampicillin
media (100 |ig/ml) to prepare starter cultures. The tubes were then incubated at 37 °C,
250 rpm, for 8 hr. The starter cultures were then diluted 1/1000 into 100 ml of
LB/ampicillin media (100 (J-g/ml) in a 500 ml flask and incubated overnight at 37 °C,
250 rpm. The plasmids were then isolated using HiSpeed Plasmid Maxi Kit (Qiagen)
according to manufacturer's instructions, and quantified using UV-Vis
spectrophotometry. The plasmid DNA was then stored at -20 °C until transfection.
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Transient Transfection of the Wild-Type BRCA1 Construct and Empty Vector Control
into SUM149PT Cells
The day before transfection, SUM149PT cells were plated at approximately
100 cells/cm2 growth area of a T-25 tissue culture flask using regular growth media.
Prior to transfection, cells were washed once with IX phosphate-buffered saline (PBS)
and replenished with 2 ml of Opti-MEM® I Reduced Serum Medium (Invitrogen). The
pcDNA3p-5i?C4i (10 ng) and pcDNA3 (10 u.g) plasmids were transfected into the
SUM149PT cells using Lipofectamine™ 2000 (10 ul) (Invitrogen), according to the
manufacturer's instructions. A cell control that was treated only with Lipofectamine™
2000 (10 (0.1) was included to monitor cytotoxicity from the transfection reagent. The
cells were incubated at 37 °C in a CO2 incubator for 24 hr (the media in the flasks was
replaced with regular growth media 6 hr after transfection).

Nuclear Protein Extraction and Quantification
The SUM149PT cells were collected into microfuge tubes 24 hr following
transfection, by scraping using a rubber policeman. The cells were pelleted by
centrifugation at 1500 rpm for 5 min, and washed once with ice-cold IX PBS. Nuclear
proteins from these cells were extracted using the NE-PER® Nuclear and Cytoplasmic
Extraction Reagents Kit (Pierce), according to the manufacturer's instructions. A
protease inhibitor cocktail (Sigma Aldrich P8340) was added to the reagents specified by
the manufacturer. The concentration of nuclear proteins extracted was then determined
using the Bio-Rad Protein Assay (Biorad), according to the manufacturer's instructions
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for the microtiter plate format. BSA was used as the standard, and the absorbance at
595 nm was measured using a microplate reader (Molecular Devices, Inc.).

Western Blot Analysis
The nuclear proteins (20 ug) were denatured by boiling for 5 min in Laemmli
Sample Buffer (Biorad), and resolved at 100 V on a Ready Gel Tris-HCl gradient gel
(4-15%) (Biorad) using IX Tris-glycine-SDS Buffer (Biroad). The Kaleidescope
Prestained Standards (Biorad) were included as molecular weight markers. Following
electrophoresis, the gel was equilibrated in IX Tris-glycine Buffer (Biorad) containing
20% (vol/vol) methanol. The proteins were then blotted overnight at 4 °C, onto a
polyvinylidene fluoride (PVDF) membrane (Amersham Biosciences) using the
Mini-Protean 3 transfer system (Biorad) (20 V), according to the manufacturer's
instructions. Following transfer, the membrane was removed from the transfer system,
oriented and blocked using 5% (wt/vol) milk for 1 hr at room temperature. Following a
brief wash in phosphate-buffered saline containing 0.05% (vol/vol) Tween-20 (PBST),
the entire membrane was cut horizontally, between the 130 kDa and 87 kDa molecular
weight markers (identified by the colors of the markers). The portion of the membrane
containing the 130 kDa and 205 kDa markers were probed overnight at 4 °C with
anti-BRCAl monoclonal antibody (2 ug/ml) (Calbiochem) in 1% (wt/vol) milk and
PBST. The other portion of the membrane containing markers between the molecular
weights 7 kDa to 87 kDa, were probed for the TATA-binding protein (TBP) (a nuclear
loading control) using anti-TBP monoclonal antibody (1/2000) (Abeam) in 1% (wt/vol)
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milk and PBST. Following a brief wash, the two portions of the membrane were
incubated in ECL peroxidase labeled anti-mouse antibody (1/5000) (Amersham
Biosciences), 3% (wt/vol) milk and PBST for 1 hr at room temperature. The membrane
was then rinsed three times in PBST, treated with ECL Western Blotting Detection
Reagents (Amersham Biosciences) according to the manufacturer's instructions, and
exposed on a HyperFilm ECL (Amersham Biosciences). The film was processed
(Konica SRX-101A Film Processor) following a 20 min exposure for BRCA1 and 1 min
exposure for TBP.

Use of the Host-Cell Reactivation (HCR) Assay to Measure BER in SUM149PT Cells
Transiently Transfected with Wild-Type BRCA1 or Empty Vector Constructs

Overview of the HCR assay for BER. The HCR assay to measure BER of 8oxodG
lesions was developed by Dr. Elizabeth Alii (Ford laboratory, Stanford University). This
assay uses recombinant adenovirus carrying a reporter gene coding for GFP (Ad-GFP).
Photodynamic treatment (PDT) of DNA, which involves treatment of DNA with a
photosensitizing dye and exposure to visible light, has previously been shown to
introduce 8oxodG lesions (Schneider, Price, Maidt, Gutteridge, & Floyd, 1990). PDT of
adenoviral virions using methylene blue (as a photosensitizer) and visible light has been
shown to specifically induce damage to the DNA with little effect on the viral capsid
(Schagen et al., 1999). In the HCR assay, the Ad-GFP virions are subjected to PDT to
induce the formation of transcription-blocking 8oxodG lesions on the GFP reporter gene.
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The damaged GFP reporter gene is then introduced into cells of interest via
adenovirus-mediated gene transfer, and allowed sufficient time for repair. If the 8oxodG
lesions on the GFP reporter gene are successfully repaired by the cellular BER pathway,
the gene undergoes host-cell reactivation, and GFP is expressed. Thus, expression of
GFP (detected using a fluorescence plate reader) indicates successful repair, whereas lack
of GFP indicates compromised repair (Figure 3).

Ad-GFP

Oxidative DNA damage

Taget cell infection

Figure 3. Overview of the host-cell reactivation assay to measure BER of 8oxodG
lesions. Recombinant adenoviruses containing a GFP reporter gene (Ad-GFP) are
subjected to photodynamic treatment (methylene blue and visible light) which induces
8oxodG lesions (O) on the GFP reporter gene, thus preventing its expression. Following
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infection of the target cells, if cellular BER is efficient, the lesions are repaired and GFP
is expressed. However, if cellular BER is compromised, the lesions are not repaired and
no GFP is expressed. Reproduced with permission from the author (Alii, 2006).

Transient transfection of the wild-type BRCA1 and empty vector constructs into
SUM149PT cells for the HCR assay. SUM149PT cells were plated 24 hr before
transfection on nine wells (2 x 105 cells/well) of a 24-well plate. Three wells were
transfected with the pcDNA3 empty vector control (1 ug/well) and labeled "Vector
Control". The next three wells were transfected with the pcDNA3$-BRCAl expression
vector (1 (j.g/well) and were labeled "BRCA1 WT". The last three wells were left
untransfected and were labeled "Cell Control" (Table 1). The transfections were
performed using Lipofectamine ™ 2000 (1 ul/well) (Invitrogen), according to the
manufacturer's instructions. After 6 hr of incubation at 37 °C with 5% CO2, the cells
were replenished with 300 ul of regular growth media and further incubated for 10-15 hr,
to allow expression of the wild-type BRCA1.
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Table 1
Designation of wells for the plating, transfection and infection of SUM149PT cells in the
HCR assay
Position of well (24-well plate)

Designation of well

Al

Vector control - "Count"

Bl

Vector control - "Undamaged"

CI

Vector control - "Damaged"

A2

BRCA1 WT - "Count"

B2

BRCA1 WT - "Undamaged"

C2

BRCA1 WT - "Damaged"

A3

Cell control - "Count"

B3

Cell control - "Undamaged"

C3

Cell control - "Damaged"

Note. Vector control = SUM149PT cells transfected with pcDNA3 empty vector;
BRCA1 WT = SUM149PT cells transfected with pcDNA3p-5i?C47 expression vector;
Cell control = untransfected SUM149PT cells; Count = well of cells that was trypsinized
and counted; Undamaged = well of cells infected with the undamaged Ad-GFP viruses
(exposed to only the photosensitizer); Damaged = well of cells infected with the damaged
Ad-GFP viruses (exposed to both the photosensitizer and visible light).

PDT and adenoviral infection. One well of cells (labeled "Count") from each of the
three sets of wells labeled "Vector control", "BRCA1 WT" and "Cell control" (Table 1)
was trypsinized, and the cells were counted using a hemacytometer. SUM149PT cells
are typically infected with 50 pfu of adenovirus per cell. The number of cells counted per
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well was then used to estimate the total volume of Ad-GFP virions required for infection.
While one batch of the Ad-GFP virions (labeled "Damaged") was subjected to PDT (i.e.,
treatment with 0.5 uM methylene blue and exposure to 2 mW/cm visible light) for
1 min, another batch (labeled "Undamaged") was treated only with 0.5 uM methylene
blue but not exposed to visible light. The PDT was carried out in the dark. In order to
reduce heat damage to the virus, the PDT was performed on ice and a dish of sterile water
was used between the light source and the plate containing the virus, to absorb heat. The
cells in the wells labeled "Damaged" and "Undamaged" (Table 1) were then infected
with the damaged virus (50 pfu/cell) and undamaged virus (50 pfu/cell) respectively. The
infection was carried out in the dark. The infected cells were then incubated at 37 °C
with 5% CO2 for 24 hr (the cells were washed with IX PBS and replenished with regular
growth media 4 hr after infection).

HCR analysis. The cells were washed 24 hr following infection, trypsinized, and
resuspended in regular growth media. The cells were centrifuged at 1500 rpm for 5 min,
washed once with IX PBS, and resuspended in 500 ul of IX PBS. The cells were then
counted and the cell suspensions were normalized to the sample containing the lowest
cell number, in a final volume of 500 ul of IX PBS. Each sample (100 ul) was aliquoted
in quadruplicates on to a black 96-well plate. Wells containing only IX PBS were used
to record background fluorescence. GFP expression was measured using a fluorescence
plate reader (Flexstation 11-384, Molecular Devices Inc.), and calculated as a ratio of the
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fluorescence readings from cells infected with the damaged virus to those infected with
the undamaged virus.
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Results

Confirmation of the Wild-Type BRCA1 Construct and the Empty Vector Control
Prior to use in the transfection of SUM149PT cells, the pcDNA3$-BRCAl and the
pcDNA3 constructs that were kindly provided by Dr. Simon Powell were confirmed by
DNA restriction analysis. While the restriction enzyme to use (PstY) for the analysis of
the pcDNA3 vector was specified by the manufacturer (Invitrogen), the enzymes to use
for the confirmation of the pcDNA3p-#/?C4./ construct were unknown. Thus, the
Webcutter 2.0 program was used to generate a list of restriction enzymes that uniquely
cut the BRCA1 coding sequence and the pcDNA3 vector backbone in the
pcDNA3(3-5i?C4i construct. From this list, Nhel (uniquely cuts the BRCA1 coding
sequence) and Xhol (uniquely cuts the vector backbone) enzymes were chosen, because
these enzymes when used to cut the pcDNA3 $-BRCAl construct will generate two
fragments of unequal sizes (1940 bp and 9766 bp) that can be easily visualized on an
agarose gel.
Following restriction analysis of the plasmids isolated from the pcDNA3 $-BRCAl
and the pcDNA3 transformed bacterial clones, the products of restriction were run on a
1% TAE-agarose gel (Figure 4). All the clones tested were found to be positive for the
respective vectors. The plasmids isolated from the clones transformed with the pcDNA3
vector, following digestion with Pstl (lanes 3 to 6), gave two bands of expected sizes
(1385 bp and 4061 bp) as specified by the manufacturer. Following digestion with Nhel
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and Xhol, the plasmids isolated from the clones transformed with the wild-type BRCA1
construct (lanes 7 and 8) gave two bands of the expected sizes (1940 bp and 9766 bp).

Lanes:

1

6p

10,000
9000
800QJ
7000

*=— -9766

Sooo
4000
3

2000-

-1940
-13-85

Figure 4. Restriction analysis of the plasmids isolated from bacterial clones transformed
with the wild-type BRCA1 or the pcDNA3 constructs. Plasmids isolated from bacterial
clones following transformation with the wild-type BRCA1 and pcDNA3 constructs were
digested with NheUXhol and Pstl respectively, and electrophoresed on a
1% TAE-agarose gel (stained with ethidium bromide). Lanes 1,9 = empty; lane 2 = 1 kb
DNA ladder; lanes 3,4,5,6 = Pstl restricted plasmids from pcDNA3 transformed clones;
lanes 7, 8= NheUXhol restricted plasmids from pcDNA3(3-#RCAi transformed clones.
Bp = base pair.

25

Confirmation of Wild-Type BRCA1 Expression in SUM149PT Cells Transfected with the
pcDNA3/3-BRCAl Expression Vector
Prior to analysis of the nuclear extracts from SUM149PT cells transfected with
wild-type BRCA1, nuclear extracts from a positive control cell line (MCF7) was analyzed
by Western blotting using the anti-BRCAl monoclonal antibody. The antibody was
found to specifically recognize the 220 kDa BRCA1 protein (Figure 5A). In our study,
transfection of the SUM149PT cells with the empty pcDNA3 vector showed no BRCA1
protein expression, whereas transfection of the pcDNA3P-Z?i?CA7 construct into these
cells showed the presence of BRCA1 proteins in the nucleus (Figure 5B).

A

MICF7

B
Lanes:

SUM149PT
1

2

BRCA1

Figure 5. Western blot analysis of nuclear extracts from MCF7 cells and SUM149PT
cells transfected with wild-type BRCA1 or the empty vector constructs. Nuclear extracts
from MCF7 cells (A) were collected, subjected to SDS-PAGE gel electrophoresis using a
4-15% gradient Tris-HCl gel. The proteins were blotted onto a PVDF membrane and the
TM

membrane was probed using anti-BRCAl monoclonal antibody and ECL peroxidase
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labeled anti-mouse antibody. TATA-binding protein (TBP) was used as a nuclear
loading control. Nuclear extracts from SUM149PT cells (B) transfected with either the
empty pcDNA3 vector (lane 1) or the wild-type BRCA1 construct (lane 2) were analyzed
as described for the MCF7 cells. kDa = kilo Dalton.

BER Activity in SUM149PT Cells Transiently Transfected with Wild-Type BRCA1 and
Empty Vector Control
The HCR assay was performed to detect the efficiency of BER in SUM149PT
cells transiently transfected with the wild-type BRCA1 and the empty vector constructs.
The green fluorescence from GFP expression was recorded in wells containing an equal
number of transfected (with pcDNA3 or BRCA1 constructs) SUM149PT cells that were
infected either with the undamaged or damaged Ad-GFP virus. The relative GFP
expression in the BRCA1 wild-type or empty vector transfected SUM149PT cells was
then calculated as a ratio of the fluorescence readings obtained from cells infected with
the damaged virus to those infected with the undamaged virus (Figure 6). An
approximately two-fold increase in relative GFP expression in cells transfected with the
wild type BRCA1 expression vector, when compared to those transfected with the empty
pcDNA3 vector was observed. Untransfected SUM149PT cells subjected to the HCR
assay showed similar relative GFP expression (0.6) when compared to that of cells
transfected with the pcDNA3 vector (0.5). This shows that the vector backbone in the
wild-type BRCA1 construct did not enhance BER activity.
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Figure 6. Relative GFP expression from the HCR assay to measure BER in SUM149PT
cells transfected with wild-type BRCA1 or empty vector constructs. SUM149PT cells
transiently transfected with either the empty vector control (SUM149PT pcDNA3) or the
wild-type BRCA1 expression vector (SUM149PT BRCA1) were subjected to the HCR
assay to measure BER as described in the Methods section. The green fluorescence was
recorded in quadruplicate wells (for each cell type) containing an equal number of cells,
using a fluorescence plate reader. The relative GFP expression for each cell type was
calculated as a ratio of the average fluorescence obtained for cells infected with the
damaged virus to that of the undamaged virus. Each bar represents the average of the
relative GFP expression for each cell type from two independent experiments. Vertical
lines represent standard errors of the means.

A few modifications to the assay methodology was later made (Alii, 2008), which
included the use of the same cell numbers for measuring GFP expression in each
experiment, in order to compare results obtained from different experiments. Using these
modifications, when the assay was later repeated several times (Alii, 2008), an
approximately four-fold increase in relative GFP expression from cells transfected with
the wild-type BRCA1 construct when compared to those transfected with the empty
vector control, was observed.
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Discussion

BRCA1 has been known as a "caretaker" of the genome (Kinzler & Vogelstein,
1997) due to its role in multiple cellular processes that maintain genomic integrity. It has
been implicated in the HR and NHEJ pathways to repair DNA double-stranded breaks
(Zhang & Powell, 2005; Zhuang et al., 2006), and in the transcription-coupled repair
(TCR) (Wang et al., 2000) and global genomic repair (GGR) (Hartman & Ford, 2002)
sub-pathways of NER. However, the role of BRCA1 in the BER pathway was unknown.
A direct correlation between cellular levels of BRCA1 and resistance to oxidative
stress has previously been reported in prostrate cancer cells (DU-145) (Bae et al., 2004)
and in mouse mammary epithelial cells (Alii, 2008). BRCA1 was found to up-regulate
the expression of antioxidant genes in the study conducted by Bae et al. (2004).
Although this may explain the BRCA1-mediated resistance to oxidative stress, we
wanted to investigate if BRCA1 was involved in the BER pathway.
A breast cancer cell line (SUM149PT) known to contain a BRCA1 truncation
mutation (2288delT) that resulted in an absence of BRCA1 protein expression was
chosen for our study. A wild-type BRCA1 expression vector and the empty vector
(lacking the BRCA1 coding sequence) were confirmed by restriction analysis prior to
their transfection into SUM149PT cells. These plasmids were previously sequenced and
were found to contain no mutations (Scully et al., 1996). Due to the large size of the
BRCA1 expression plasmid (which would require the use of multiple primers), we did not
re-sequence the plasmid following restriction analysis. However, following transfection
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of SUM149PT cells with the wild-type BRCA1 construct, we detected (by Western
blotting) the presence of full-length BRCA1 proteins in the nucleus. This also suggests
that the BRCA1 proteins were functional, since truncated BRCA1 proteins have been
shown to be unable to translocate into the nucleus to form nuclear foci and function in
DNA damage response (Scully et al., 1999). The SUM149PT cells transfected with the
wild-type BRCA1 expression vector or the empty vector were subjected to the HCR assay
to monitor in vivo BER activity. Results from our study suggested that SUM149PT cells
expressing wild-type BRCA1 proteins have enhanced BER activity.
BRCA1 may enhance BER activity through transcriptional regulation or direct/
indirect interactions with the proteins involved in the pathway. An immunoprecipitated
BRCA1 protein complex containing USF2, a transcription factor, has been shown to
specifically bind a novel consensus DNA sequence (TTC(G/T)GTTG) (Cable et al.,
2003). Screening of the regulatory regions of genes directly or indirectly involved in
BER for this consensus DNA sequence, may enable identification of BER genes (if any)
that are transcriptionally regulated by BRCA1. BRCA1 has been shown to interact with
components of the basal transcriptional machinery such as RNA polymerase II
holoenzyme and histone deacetylases (Lane, 2004; Monteiro, 2000). Thus, it may
nonspecifically regulate transcription of BER related genes. BRCA1 may also facilitate
the access of BER proteins to the oxidized bases through its association with the
chromatin remodeling proteins SW1 and SNF (Bochar et al., 2000).
The tumor suppressor p53 has been shown to enhance the hOGGl- and
APE 1-mediated cleavage steps in the BER pathway (Achanta & Huang, 2004). BRCA1,
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through its interaction with p53 (Zhang et al, 1998), may indirectly regulate BER
activity. On the other hand, BRCA1 may interact directly with the proteins involved in
BER through its BRCT domain. This domain, found in the carboxyl terminal end of the
BRCA1 protein, is often found in other proteins involved in DNA repair and maintenance
of genomic stability (Yarden & Papa, 2006). Such proteins have the ability to form
homo- and heterodimers through the interaction of their BRCT domains (Caldecott,
2003). The XRCC and Ligase III proteins involved in BER have been shown to
heterodimerize through their BRCT domains (Dulic et al., 2001). It is likely that
heterodimerization of the BRCA1 protein with either of these proteins could enhance
their activity in the BER pathway.
In conclusion, preliminary investigations in our study have shown that BRCA1
enhances the BER pathway. These results will have to be confirmed using another assay
for BER. Although it has been shown that immortalized cell lines retain many of the
characteristics of the primary tissue (Neve et al., 2006), upon long-term culture, they may
acquire new mutations in vitro. Thus, in the future, it may be useful to monitor BER in
BRCA1 -mutated primary breast cancer cells, before and after transfection with a BRCA1
expression vector. Besides the up-regulation of antioxidant genes, the putative
involvement of BRCA 1 in the BER pathway suggests yet another mechanism by which
the tumor suppressor may resist oxidative DNA damage in mammary tissue. The lack of
these critical functions may explain the increased susceptibility to oxidative DNA
damage previously observed in BRCA 1 -mutated breast cancer cells. Future research on
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the precise role of BRCA1 in the BER pathway may facilitate the development of
improved therapeutic strategies for BRCA1-associated breast and ovarian cancers.
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CHAPTER TWO

DEVELOPMENT OF A NOVEL ASSAY TO MEASURE IN VIVO BER

Introduction

The 8oxodG lesions are one of the most frequently observed oxidation products
(Poulsen, Prieme, & Loft, 1998) and have been commonly used as indicators of cellular
oxidative stress. These lesions are excised by the hOGGl DNA glycosylase (Rosenquist,
Zharkov, & Grollman, 1997) and repaired primarily using the BER pathway (Lindahl,
1993). The efficiency of cellular BER of 8oxodG lesions may be measured using one of
two methods. The first method involves monitoring the disappearance of 8oxodG lesions
with time, on genomic DNA, following induction of cellular oxidative stress. The second
method involves monitoring the disappearance of 8oxodG lesions on a DNA repair
substrate either in vitro or in vivo.

Nonsubstrate Based Methods to Measure BER
Some of the techniques available to measure BER do not use DNA repair
substrates. Instead, they measure BER of 8oxodG lesions by monitoring the
disappearance of the lesions on cellular genomic DNA, following exposure of the cells to
oxidizing agents. High performance liquid chromatography with electrochemical
detection (HPLC-ECD) has been used to measure 8oxodG bases on genomic DNA,
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following digestion of DNA using nuclease PI and alkaline phosphatase (Anson, Hudson,
& Bohr, 2000; Degan et al., 1995; Floyd, Watson, Wong, Altmiller, & Rickard, 1986).
This method is expensive, requires a large sample volume and is capable of generating
artifacts during sample preparation and chromatography (Ravanat et al., 2002). A
common enzymatic method used to measure cellular 8oxodG levels following induction
of oxidative stress involves the conversion of the 8oxodG lesions into DNA strand breaks
using formamidopyrimidine DNA glycosylase. The breaks are subsequently detected
using the comet assay (reviewed by McKelvey-Martin, Green, Schmezer, Pool-Zoberl, &
Collins, 1993). This assay is inexpensive, requires very small amounts of DNA, and
enables detection of heterogeneity in a cell population by measuring damage in single
cells (Collins, Cadet, Moller, Poulsen, & Vina, 2004). However, this assay may
sometimes underestimate 8oxodG levels due to inaccessibility of the lesions to the
enzyme (occurs when the lesions are present in DNA loops) and due to the insensitivity
of the assay above a certain level of DNA breakage (occurs when the tail end of the
comet is saturated) (Collins & Dusinska, 2002; Collins et al., 2008). In addition, the
assay is difficult to reproduce and requires careful optimization of experimental
conditions to avoid detection of nonspecific strand breakage.
Other assays use fluorescein isothiocyanate (FITC) conjugated 8oxodG binding
proteins to detect cellular 8oxodG lesions by fluorescence microscopy or flow cytometry,
following exposure of cells to oxidizing agents. Although simple and inexpensive, these
methods suffer from high levels of background fluorescence due to either nonspecific
binding of the FITC-conjugated proteins, or high basal levels of endogenous 8oxodG
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lesions which occur as a result of cellular metabolism. As a result, the assay is not
sensitive enough to detect differences in 8oxodG levels before and after treatment with
oxidizing agents (unpublished observations, Ford laboratory).
Immunoaffinity based methods for the detection and quantification of 8oxodG
lesions have been previously described (Degan, Shigenaga, Park, Alperin, & Ames, 1991;
Musarrat & Wani, 1994; Yin et al., 1995). An immunoaffmity-chromatography based
8oxodG ELISA using monoclonal antibodies (Yin et al., 1995) showed results
comparable to those obtained using HPLC. Depending on the specificity of the antibody
used, ELISA is a convenient, sensitive and relatively inexpensive assay to quantify
8oxodG lesions. A number of commercial 8oxodG ELISA kits (Trevigen Inc., Japan
Institute for the Control of Aging, Genox Corp.) have recently been developed to
measure 8oxodG levels in urine and serum samples. However, besides 8oxodG lesions,
these kits can also detect and quantify RNA-based guanine oxidation products. If these
kits were to be used with genomic DNA, they would then not only measure 8oxodG
levels on the DNA, but also measure guanosine or its oxidation products (such as
8-bromoguanosine, 8-mercaptoguanosine, and N2-methylguanosine, etc.) on any
contaminating RNA. Thus, when used with genomic DNA, these kits may not reliably
indicate the efficiency of cellular BER of 8oxodG lesions.

Substrate Based Methods to Measure BER
In vitro studies using cell extracts and plasmid DNA substrates have greatly
advanced our understanding of the enzymology and steps involved in the repair of
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8oxodG lesions (Dianov, Bischoff, Piotrowski, & Bohr, 1998; Fortini et al., 1999; Hazra,
Izumi, Maidt, Floyd, & Mitra, 1998). However, one study (Cappelli, Degan, & Frosina,
2000) reported the poor repair of 8oxodG lesions in vitro, using cell extracts from human
fibroblast GM5757. In vitro BER may not be an accurate model of in vivo repair due to
potential modifications of physiological conditions, disruption of repair protein
complexes, interference from reagents in cell lysis buffers, and inconsistencies in the
performance of cell extracts. In addition, the use of radiolabeled reagents in most of the
in vitro assays further imposes cost and safety limitations.
The HCR assay described in chapter one is an in vivo (cell-based) BER assay,
that monitors the repair of 8oxodG lesions on the GFP-coding region of recombinant
adenoviruses (Ad-GFP). Although it measures repair in vivo, it is an end-point assay; the
repair of 8oxodG lesions is measured by the expression of functional GFP 24 hr after
infection. Thus, the HCR assay cannot obtain steady-state measurements of in vivo BER.
In this study, we have designed a novel assay to measure the in vivo BER of
8oxodG lesions using a biotin-tagged oligonucleotide DNA substrate, containing a single
8oxodG lesion on the untagged DNA strand (target strand). Briefly, the assay involves
the transfection of the biotin-tagged substrate DNA into target cells and incubation for an
increasing period of time to allow repair of the 8oxodG lesions. The cells are then lysed
and the biotin-tagged substrate DNA is captured on streptavidin-coated beads and
denatured, to isolate the untagged target DNA strand from the biotin-tagged
complementary DNA strand. The 8oxodG lesions on the target DNA strands are then
measured using the HT 8oxodG competitive ELISA Kit (Trevigen Inc.). The amount of
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lesions detected on the target DNA is inversely proportional to the efficiency of cellular
BER. When used with the tagged substrate DNA in this assay, the 8oxodG ELISA may
provide a more reliable estimate of the efficiency of cellular 8oxodG BER when
compared to its use with genomic DNA, because the tagged substrate DNA can be
captured and purified from any contaminating DNA or RNA.
This chapter describes the design of this novel assay for measuring BER of
8oxodG lesions and optimization of the experimental conditions for some of the steps in
the assay. The optimal working conditions for the assay were determined from the last
step of the assay to the first, and each section of this chapter has been written in the same
order. That is, the optimization experiments were performed first for the ELISA step of
the assay, followed by the binding of the biotin-tagged substrate DNA to the
streptavidin-coated beads, its denaturation and quantification, and finally, the transfection
of the substrate DNA into target cells. This order was chosen since knowledge of the
minimal amount of DNA required for the ELISA would enable an estimation of the
amount of DNA to be used for titration of the streptavidin-coated beads, and ultimately
for transfection.
In the future, following validation of the assay in vivo, it may be used to identify
potential cancer genes that regulate the BER pathway.
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Materials and Methods

Single-Stranded DNA Oligonucleotides
The following oligonucleotide DNA strands were used to prepare the substrate
and control DNA:
1. Biotinylated DNA strand (nontarget DNA strand) (Operon)
The nontarget DNA strand (28-mer) has a biotin-TEG tag at the 3' end and
consists of the following sequence:
5'-GCAGCCCGGGGGATCCACTAGTTCTAAG-Bt-3' (where Bt represents Biotin).
2. + 8oxodG DNA strand (target DNA strand) (Midland Certified Reagents)
The target DNA strand (24-mer) has a single 8oxodG lesion at position 10 (from
the 5' end) and consists of the following sequence:
5'-GAACTAGTGOATCCCCCGGGCTGC-3' (where O represents 8oxodG)
3. -8oxodG DNA strand (control DNA strand) (Operon)
The control DNA strand (24-mer) is identical in nucleotide sequence to the target
DNA strand, but with a guanine instead of the 8oxodG lesion at position 10. It has the
following sequence: 5"-GAACTAGTGGATCCCCCGGGCTGC-3'.

Gel Analysis of the Single-Stranded DNA Oligonucleotides
The single-stranded +8oxodG, -8oxodG and biotinylated DNA oligonucleotides
were resuspended in IX Tris-EDTA (TE) buffer, aliquoted, and stored at -20 °C. The
DNA oligonucleotides (50 ng) were then denatured by heating at 90 °C for 5 min in a
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solution containing 95% (vol/vol) formamide, 30% (vol/vol) glycerol, 0.25% (wt/vol)
bromophenol blue and 0.25% (wt/vol) xylene cyanol FF (Sambrook, Fritsch, & Maniatis,
1989). The denatured DNA samples were placed on ice until they were ready to load
onto a 15% Tris-borate-EDTA (TBE)-polyacrylamide 7 M urea gel. The gel was prerun
for 30 min at 110 V. The samples were then loaded and electrophoresed at 110 V for
approximately 1 hr. A 10 bp DNA ladder (Integrated Technologies) was denatured as
described for the samples, and included in the gel. The DNA bands were visualized
using 300 nm UV illumination (Chemilmager 4400, Alpha Innotech), following staining
with SYBR® Green II (Invitrogen) according to the manufacturer's instructions. SYBR®
Green II was used because it binds with higher affinity to single-stranded than
double-stranded DNA (Invitrogen).

Preparation of the Substrate and Control DNA
Annealing. The substrate DNA (+ 8oxodG/biotinylated DNA) and the control DNA
(- 8oxodG/biotinylated DNA) were prepared by annealing the single-stranded
oligonucleotides as previously described (Achanta & Huang, 2004). Briefly, the
+8oxodG or -8oxodG DNA strands (2 pmol/|j.l) and the biotinylated DNA strands
(1 pmol/(il) were mixed in an annealing buffer consisting of a final concentration of
10 mM Tris-hydrochloride (Tris-HCl) (pH 7.5), 5 mM magnesium chloride, and 30 mM
sodium chloride (NaCl). The solution was heated to 85 °C and allowed to gradually cool
to room temperature. The annealed DNA was aliquoted and stored at -20 °C.

39

Quantification. The annealed substrate and control DNA were quantified by
fluorimetry using SYBR® Green I (Invitrogen). The NoLimits™ 25 bp DNA fragment
(Fermentas) was used to generate a DNA standard curve ranging from 0-500 ng/ml. The
SYBR® Green I dye was diluted (1/5000), and 500 ul of the diluted dye was added to
500 ul of diluted annealed DNA (1/100 or 1/1000), and the solution was mixed well.
Following incubation at room temperature (in the dark) for 5 min, 200 ul aliquots of the
solution were loaded in quadruplicate wells of a black 96-well plate. Fluorescence was
recorded using a fluorescence plate reader (Flexstation 11-384, Molecular Devices Inc.) at
the excitation and emission wavelengths of 497 nm and 520 nm respectively.

Gel analysis. The annealed substrate and control DNA (25 ng) were mixed with
30% (vol/vol) glycerol, 0.25% (wt/vol) bromophenol blue and 0.25%o (wt/vol) xylene
cyanol FF (Sambrook et al., 1989), and electrophoresed at 110 V on a
15% nondenaturing TBE-polyacrylamide gel. The gel was stained using SYBR Green I
(Invitrogen) according to the manufacturer's instructions, and visualized using 300 nm
UV illumination. A 10 bp DNA ladder (Invitrogen) was also included.

8oxodG Competitive ELISA
The reagents from the HT 8oxodG ELISA Kit (Trevigen), including the 8oxodG
coated ELISA plate, the standards consisting of 8oxodG bases and the anti-8oxodG
antibody, were used to quantify 8oxodG lesions in our BER assay. The ELISA was
performed according to the manufacturer's instructions. Briefly, the 8oxodG standards
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and the single-stranded +8oxodG or -8oxodG DNA (5 ng each) were added to triplicate
wells (50 ul/well) of the 96-well plate precoated with 8oxodG lesions. Then, diluted
anti-8oxodG monoclonal antibody (50ul/well) was added, the plate was covered, and
incubated at 37 °C for 1 hr. Following incubation, the wells were washed six times with
the IX wash buffer provided (200ul/weli). Diluted horseradish peroxidase (HRP)
conjugated anti-mouse secondary antibody (100 ul/well) was then added; the plate was
covered and incubated for 1 hr at 37 °C. The wells were then washed as described
before. The 3,3',5,5' - tetramethylbenzidine (TMB) substrate (100 ul/well) was added to
the wells and the plate was incubated in the dark for 15 min. The reaction was stopped
using the stop solution provided (1 N hydrochloric acid) and the absorbance values at
450 nm was measured using a microplate reader (Molecular Devices Inc.). The intensity
of the yellow color is inversely proportional to the concentration of 8oxodG in the sample
or standard. The 8oxodG standard curve was used to determine the amount of 8oxodG
lesions on the +8oxodG and -8oxodG DNA.

Titration of the Amount of Streptavidin-Coated Magnetic Beads to use in the BER Assay
The Dynabeads®M-270 Streptavidin (Invitrogen) were washed and prepared for
binding according to the manufacturer's instructions. The double-stranded control DNA
(100 ng) was mixed with the beads (10 ug, 50 ug, 100 ug, 150 ug) and incubated
according to the manufacturer's instructions. Briefly, the DNA and the beads were
mixed in a solution containing a final concentration of 5 mM Tris-HCl (pH 7.5), 0.5 mM
EDTA and 1 M NaCl (IX Binding and Washing [B&W] buffer) and incubated at room
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temperature for 15 min. The tube was tapped every 3 min to resuspend the beads. At the
end of the incubation, the tubes were placed on a magnetic stand (Promega) for 2 min and
the supernatant was removed and discarded. The beads were then washed twice in the
IX B&W buffer. The beads (containing the bound, double-stranded control DNA) were
then resuspended in 25 jul of 0.1 M sodium hydroxide (NaOH) to denature the
double-stranded DNA into single-stranded -8oxodG and biotinylated DNA strands. The
solution was incubated at room temperature for 5 min (on a shaker). The tube was then
placed on a magnet for 2 min, after which the supernatant (containing the denatured,
untagged -8oxodG DNA strands) was collected and stored at 4 °C. A small volume
(5 JJ.1) of the supernatant eluted from each of the four experiments (10 ug, 50 (ig, 100 u.g,
150 (ig beads) was electrophoresed on a 12% TBE-poiyacrylamide 8.3 M urea gel as
described before ("Gel analysis of the single-stranded oligonucleotides" section of this
chapter). A fixed amount of the -8oxodG DNA strand (11 ng) was also electrophoresed
to serve as a reference band of known concentration while estimating the amount of DNA
in the sample lanes. A 10 bp DNA ladder (Integrated Technologies) was also included.
The intensity of the DNA bands was determined using Image J software vl .37
(developed by Rasband, 2006).

Quantification of DNA
The single-stranded -8oxodG DNA was used to generate a standard curve ranging
from 0-50 ng/ml (in 10 ng/ml increments). The fluorescent dyes SYBR® Green II
(Invitrogen) and Quant-iT™ Oligreen ssDNA Reagent (Invitrogen) were diluted
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according to the manufacturer's instructions. The DNA standards (500 ul) were mixed
with either of the two diluted dyes (500 ul), incubated at room temperature (in the dark)
for 5 min, and aliquots (200 ul) were loaded in quadruplicate wells of a black 96-well
plate. The fluorescence was recorded using a fluorescence plate reader at the
excitation/emission wavelengths of 497 nm/520 nm and 480 nm/520 nm for the SYBR®
Green II and Quant-iT™ Oligreen dyes respectively.

Cell Lines and Media
SUM149PT cells were cultured in Ham's F12 media supplemented with
10% (vol/vol) FBS, IX P/S/F, 5 ug/ml insulin, 1 ug/ml hydrocortisone and
10 mM HEPES. MCF7 cells were cultured in media containing DMEM, 10% FBS and
IX P/S/F. All the cells were maintained in 5% C0 2 at 37 °C.

Selection of a Suitable Transfection Reagent
Transfection. SUM149PT cells were plated (1 x 105 cells per well) on a 24-well plate
using 500 ul of regular growth media, and allowed to adhere overnight. Double-stranded
control DNA (800 ng) was transfected into each well using either Lipofectamine™ 2000
(2 ul/well) (Invitrogen) or Oligofectamine™ (2 ul/well) (Invitrogen) transfection reagent,
according to the manufacturer's instructions. In order to monitor cell death from
treatment with the transfection reagents, untransfected cell controls that were treated only
with either of the two reagents were prepared. The cells were incubated for 4 hr at 37 °C
in a CO2 incubator.
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Cell lysis, DNA capture, denaturation, and quantification following transfection.
Following transfection of the control DNA and incubation for 4 hr, the cells were
trypsinized, quenched using regular growth media and centrifuged at 1500 rpm for 5 min.
The cell pellet was washed once in 500 ul of IX PBS. The pellet was then resuspended
in 20 ul of cell lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, and 1% Triton-X 100). Protease inhibitor cocktail (IX) (Sigma Aldrich
P8340) was added to the lysis buffer prior to use. The cells were rotated at 4 °C for 1 hr
and centrifuged at 14,000 rpm for 10 min (Hou, Prasad, Asagoshi, Masaoka, & Wilson,
2007). The supernatant was removed and stored at -20 °C until future use.
The Dynabeads® M-270 Streptavidin (Invitrogen) were washed and prepared for
binding according to the manufacturer's instructions. The cell lysate was thawed on ice
prior to use. The NaCl and EDTA concentrations in the lysate were adjusted prior to the
addition of streptavidin-coated magnetic beads, to facilitate bead binding. The
recommended bead binding conditions are 5 mM Tris HC1 (pH 7.5), 0.5 mM EDTA, and
1 M NaCl (Invitrogen). The beads (850 ug) were then added to the cell lysate, incubated
to allow for DNA capture, and washed, according to the manufacturer's instructions. The
DNA bound to the beads was then denatured using 0.1 M NaOH and the supernatant was
collected as described before ("Bead titration" section of this chapter). The DNA
recovered in the supernatant was then quantified using the Quant-iT™ OliGreen®
ssDNA reagent (Invitrogen), as described before ("DNA quantification" section of this
chapter).
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Transfection of Control and Substrate DNA into SUM149PT and MCF7 cells, DNA
Capture and Denaturation
SUM149PT and MCF7 cells were plated as described before ("Selection of a
transfection agent" section of this chapter). The cells were transfected with the
double-stranded control DNA (800 ng) or the substrate DNA (800 ng), using
Lipofectamine™ 2000 (2 ul/well) (Invitrogen) according to the manufacturer's
instructions. Following incubation for 4 hr at 37 °C, the cells were collected, lysed and
the transfected DNA was captured and denatured as described before ("Selection of a
transfection agent" section of this chapter).

Gel Analysis of DNA Recoveredfollowing Capture and Denaturation
The supernatant containing the DNA recovered following denaturation of the
captured DNA was heated at 90 °C for 5 min in an 80% (vol/vol) formamide loading
buffer (Teknova) and immediately loaded on a 12% TBE-polyacrylamide 8.3 M urea gel.
The gel was run at 12 W for around 30 min, after which it was stained with SYBRR
Green II (Invitrogen) according to manufacturer's instructions. The DNA bands were
visualized using 300 nm UV illumination. A 10 bp DNA ladder (Integrated
Technologies) was also included.

Preparation and Gel Analysis of Untransfected SUM149PT Cell Controls
SUM149PT cells were plated in two wells of a 24-well plate as described before
("Selection of a transfection agent" section of this chapter). Both wells of cells were
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treated with Lipofectamine ™ 2000 (2 ul/well) according to manufacturer's instructions,
and incubated for 4 hr at 37 °C in a CO2 incubator. Cells from both the wells were lysed,
and the lysate from only one well of cells was subjected to bead capture and denaturation
as described before ("Selection of a transfection agent" section of this chapter). The
supernatant obtained following denaturation, along with the lysate from the other batch
of SUM149PT cells were electrophoresed on a 12% polyacrylamide 8.3 M urea gel at
110 V. The electrophoresed DNA bands were stained using SYBR® Green II, and
visualized using 300 nm UV illumination. A 10 bp DNA ladder (Integrated
Technologies) was also included.
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Results

Substrate and Control DNA Oligonucleotides
The 8oxodG BER assay uses a double-stranded oligonucleotide DNA substrate
(also represented as "+ 8oxodG/biotinylated DNA") that consists of a biotinylated DNA
strand (nontarget strand) that is base paired to an untagged DNA strand containing a
single 8oxodG lesion (+8oxodG or target strand). A double-stranded control DNA (also
represented as "- 8oxodG/biotinylated DNA") that is identical to the substrate DNA,
except that it has a guanine instead of the 8oxodG lesion on the untagged strand
(-8oxodG or control strand), was used for the optimization experiments.

Overview of the in vivo 8oxodG BER Assay
In the first step, the substrate DNA is transfected into target cells and incubated
for an increasing period of time to allow repair of the 8oxodG lesion. The cells are then
lysed and the biotinylated substrate DNA is captured using streptavidin-coated magnetic
beads. In the presence of a magnet, the strand containing the 8oxodG lesion (+8oxodG or
target strand) is denatured and isolated from the streptavidin-bound biotinylated strand
(nontarget strand). The isolated DNA is then quantified and subjected to an 8oxodG
competitive ELISA to measure the disappearance of 8oxodG lesions over time (Figure 7).
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Figure 7. Overview of the in vivo 8oxodG BER assay
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Gel Analysis of the Single-Stranded DNA Oligonucleotides
In order to verify the lengths of the synthesized single-stranded DNA
oligonucleotides, and to establish the experimental conditions for the denaturing gel
electrophoresis, the +8oxodG, -8oxodG and biotinylated DNA oligonucleotides were
electrophoresed on a denaturing gel (Figure 8) prior to being used for preparation of the
substrate and control DNA.

Lanes
Bp
60

50
40
30

•*—- Biotinylated DNA
strand

25

*—- -SoxodG or +SoxodG DNA
strands

20
15
10

Figure 8. Gel analysis of the single-stranded DNA oligonucleotides used in the in vivo
8oxodG BER assay. The single-stranded -8oxodG, +8oxodG and biotinylated DNA
oligonucleotides (50 ng) were denatured by heating at 90 °C for 5 min in 95% (vol/vol)
formamide. The samples were loaded on a 15% TBE-polyacrylamide 7 M urea gel,
stained using SYBRR Green II and visualized using 300 nm UV illumination.
Lane 1: 10 bp DNA ladder; lane 2: -8oxodG DNA strand; lane 3: +8oxodG DNA strand;
lane 4: biotinylated DNA strand.

On electrophoresis, the 24-mer -8oxodG DNA (lane 2) and +8oxodG DNA (lane
3) oligonucleotides were found to comigrate with and slightly above a 25-mer DNA
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marker, respectively. We believe that the +8oxodG strand migrated slower than expected
due to the presence of the 8oxodG lesion. Besides the 24-mer band, a faint band which
was around 50 bases in length was also observed in the -8oxodG DNA lane. This was
probably formed due to the self-annealing of the 24-mer -8oxodG DNA strands, since the
DNA has self-complementary regions of guanine and cytosine bases. The 28-mer
biotinylated DNA strand (lane 3) was found to migrate slightly above a 30-mer DNA
marker. The slower migration was probably due to the presence of the biotin tag. Both
the +8oxodG and biotinylated DNA were found to stain less strongly with the SYBRK
Green II dye when compared to the -8oxodG DNA. Due to their high tendency to donate
electrons, guanine bases have been shown to be efficient fluorescence quenchers
(Lacowicz, 2006). The 8oxodG bases have an oxidation potential that is approximately
0.5 V lower than that of guanine (Stover, Ciobanu, Cliffel, & Rizzo, 2007). Thus, we
believe that the low oxidation potential of the 8oxodG lesion in the +8oxodG DNA may
quench the fluorescence of the dye. We also speculate that the presence of the biotin tag
in the biotinylated DNA reduces the surface adsorption of the monomeric dye to the
DNA.

Preparation of Substrate and Control DNA
The substrate and control DNA were prepared by annealing the single-stranded
+8oxodG and -8oxodG oligonucleotides respectively to the biotinylated DNA
oligonucleotide in a 2:1 ratio. This ratio was used to ensure the annealing of all the
biotinylated DNA strands, so that they would not compete with the annealed substrate or
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control DNA for binding to the streptavidin-coated beads during the optimization
experiments. The annealed substrate and control DNA were quantified using SYBR®
Green I, since this dye binds preferentially to the minor groove of double-stranded DNA
(Zipper, Brunner, Bernhagen, & Vitzthum, 2004). Following annealing, the DNA was
analyzed on a 15% nondenaturing polyacrylamide gel (Figure 9).

Lanes

Bp

60
50
40

• - = Annealed control or
substrate DNA

30:
!

Self-annealed -SoxodiG or
+80X0dG DNA

*»f<~

20

Figure 9. Gel analysis of the annealed double-stranded substrate and control DNA. The
annealed substrate and control DNA (25 ng each) were electrophoresed on a
15% TBE-polyacrylamide gel. The gel was stained using SYBR® Green I and visualized
using 300 nm UV illumination. Lane 1: 10 bp DNA ladder; lane 2: annealed control ds
DNA; lane 3: annealed substrate ds DNA. ds = double-stranded

Following annealing, we would expect three species of DNA on the
nondenaturing gel: (a) the annealed double-stranded substrate or control DNA,
(b) self-annealed (-24 bp) +8oxodG or -8oxodG DNA (since this was used in excess of
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the biotinylated DNA for the annealing), and (c) self-annealed (-28 bp) biotinylated
DNA (if annealing was not 100%). Two bands were seen in both the annealed substrate
and control DNA lanes; one band was approximately 24 bp in length and the other was
approximately 45 bp in length. We believe that the 24 bp band corresponds to the
self-annealed +8oxodG or -8oxodG DNA, and the 45 bp band corresponds to the
annealed substrate or control DNA. No band approximately 28 bases in length
(corresponding to self-annealed biotinylated DNA) was observed in the gel. This
suggests that either all the biotinylated DNA was annealed (which would then suggest
that the annealing was 100% successful), or the amount of biotinylated DNA in the gel
was below the limit of sensitivity of the SYBR® Green I dye. In the future, it may be
useful to determine the extent of annealing by monitoring the hyperchromicity shift at
260 nm.

Specificity of the 8oxodG Competitive ELISA
Since the HT 8oxodG ELISA Kit (Trevigen) was originally developed for the
quantification of 8oxodG lesions in urine and serum samples, the specificity and
efficiency of the ELISA when used with the oligonucleotides in our BER assay was first
evaluated. Specificity of the 8oxodG ELISA may be defined as its ability to discriminate
between DNA containing 8oxodG lesions and DNA lacking the lesions. Thus, in order to
monitor ELISA specificity, the single-stranded +8oxodG DNA containing the 8oxodG
lesion and the -8oxodG DNA lacking the lesion were used as positive and negative
controls respectively.
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In order to determine the amount of +8oxodG and -8oxodG DNA to be used for
monitoring specificity, we first had to determine the range of DNA concentrations that
could be used with the 8oxodG ELISA, so that the 8oxodG levels quantified are within
the detection range of the ELISA. The preestablished sensitivity of the 8oxodG ELISA
was 1.9 ng of 8oxodG/ml, and its detection range was 1.875-60 ng of 8oxodG/ml
(Trevigen). Thus, the 8oxodG detection range in the 50 ul assay volume (per well) was
between 0.09375-3 ng of 8oxodG lesions. We calculated that 1 ng of our +8oxodG DNA
had 0.04683 ng of 8oxodG lesions. Thus, the range of+8oxodG DNA that may be used
in the 8oxodG ELISA was between 2-64 ng/well. To determine the specificity of the
ELISA and to optimize its conditions, from this range, we used 5 ng/well of+8oxodG
and -8oxodG DNA oligonucleotides. This was chosen to minimize the amount of DNA
to be used in the BER assay. The specificity of the ELISA was measured as the
difference in absorbance values (AOD450) obtained for equal amounts of+8oxodG and
-8oxodG DNA. The higher the specificity of the assay the greater the difference in
absorbance values between the two DNA.
First, the specificity of the ELISA was monitored in the presence of two blocking
agents: FBS (2% and 10% [vol/vol]) and BSA (1% [wt/vol]) (Figure 10A). Incubation of
the wells with 2% FBS (150 ul/well) for 1 hr at 37 °C gave the highest specificity
(AOD450 = 0.26). Second, in order to identify the optimal concentration of anti-8oxodG
antibody, the specificity of the ELISA was monitored at increasing (1/250, 1/500, 1/1000,
1/2000) primary antibody dilutions (Figure 10B). A 1/250 dilution of the primary
antibody gave the highest specificity (AOD450 = 0.33). Third, to determine the optimal
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incubation temperature following the addition of the anti-8oxodG antibody to the
+8oxodG or -8oxodG DNA in the wells, the specificity of the ELISA was monitored at
different incubation temperatures (25 °C and 37 °C) (Figure IOC). Room temperature
incubation gave higher specificity when compared to that at 37 °C (AOD450 = 0.33).
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Figure 10. Specificity of the 8oxodG ELISA at different assay conditions. The
+8oxodG and -8oxodG DNA (5 ng each) were subjected to the 8oxodG ELISA after
blocking the wells (A) with either 2% FBS, 10% FBS or 1% BSA for 1 hr at 37 °C, or at
different dilutions of the anti~8oxodG antibody (B), or using different temperatures for
incubation of the anti-8oxodG antibody with the single-stranded +8oxodG or -8oxodG
DNA (C). The specificity was measured as the difference in end absorbance values
(AOD450) obtained by subtracting the OD450 values of + 8oxodG DNA from those of
the -8oxodG DNA. The higher the assay specificity, the greater will be the difference in
absorbance values between the two DNA. The vertical lines depict the standard
deviation. The bars lacking vertical lines represent the means for which the standard
deviation was zero.

Efficiency of the 8oxodG Competitive ELISA
The efficiency of the 8oxodG ELISA was determined using the optimal assay
conditions established in previous experiments (Figure 10 A, B, C). The amount of
8oxodG lesions quantified in 5 ng of+8oxodG DNA from two independent experiments
(done using two different ELISA plates) were 0.1187 ng and 0.0982 ng of 8oxodG
lesions. The average amount of 8oxodG lesions determined for the two experiments was
0.1085 ng lesions. The standard curve and sample absorbance values from one
representative experiment have been shown in Figure 11. The figure also shows that the
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average absorbance for the -8oxodG DNA strand was near that observed for the 0 n
standard.
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c.
Samples

Average absorbance
(OD 450 nm)

-8oxodGDNA

1.650

+8oxodGDNA

1.342

Concentration of 8oxodG lesions in
5 ng of+8oxodG DNA = 2.375 ng/ml

Figure 11. Efficiency of the 8oxodG competitive ELISA. The standard curve (A),
average absorbance (OD450) values of the standards (B), and average OD450 values of
the -8oxodG DNA (5 ng) and +8oxodG DNA (5 ng) (C) are shown. The concentration of
8oxodG lesions in the +8oxodG DNA was determined using the standard curve. The
results shown are representative of two independent experiments.

We had previously calculated that 0.04683 ng of 8oxodG lesions are present in
1 ng of +8oxodG DNA. Thus, we theoretically expected 0.2342 ng of 8oxodG lesions in
5 ng of the +8oxodG DNA. Since the ELISA detected only 0.1085 ng of the lesions in
5 ng of the +8oxodG DNA, its efficiency was approximately 46.33%.
Once the efficiency was determined, the range of+8oxodG DNA concentrations
that could be used with the 8oxodG ELISA was recalculated; the theoretical amount of
+8oxodG DNA that may be used after correction for ELISA efficiency is 4.3-138.4
ng/well.

57

In vitro Validation of the 8oxodG Competitive ELISA for Use in the BER Assay
At the end of the capture and denaturation step in the BER assay, the supernatant
isolated is likely to have the following DNA species: repaired +8oxodG DNA strands (no
8oxodG lesions), and unrepaired +8oxodG DNA strands (with 8oxodG lesions).
Depending on the efficiency of BER in the target cells, the ratio of repaired to unrepaired
+8oxodG DNA may range from 1:0 to 0:1. We wanted to see if the 8oxodG ELISA was
capable of effectively measuring 8oxodG lesions in the unrepaired DNA, against a
background of repaired DNA. Thus, we attempted to simulate the outcome of the BER
assay in order to validate the 8oxodG ELISA for use with the assay.
In this experiment, the -8oxodG DNA strand was used to represent repaired DNA
and the +8oxodG DNA strand was used to represent the unrepaired DNA. The -8oxodG
DNA strands were spiked with an increasing amount of+8oxodG DNA, while keeping
the total amount of DNA constant (100 ng) (Table 2). The amounts of+8oxodG DNA
used were within the theoretical detection range of the ELISA (4.3-138.4 ng/well). The
ability of the ELISA to detect increasing amounts of 8oxodG lesions in the +8oxodG
DNA (unrepaired DNA) against a background of-8oxodG DNA (repaired DNA) was
then determined (Figure 12).
The 8oxodG ELISA showed the ability to detect and quantify 8oxodG lesions on
the +8oxodG DNA in a dose-dependent manner, in the presence of different amounts of
-8oxodG DNA. This suggests that the presence of the repaired DNA will not interfere
with the quantification of lesions on the unrepaired DNA (at least when the total amount
of repaired and unrepaired DNA together is < 100 ng). Thus, the 8oxodG ELISA may be
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used in the BER assay to measure the decrease in the amount of 8oxodG lesions on the
+8oxodG DNA, seen with time. This experiment may be used in the future to generate a
standard curve to estimate the amount of repaired versus unrepaired target DNA
recovered from the target cells.

Table 2
Amount of+8oxodG and -8oxodG DNA used for the in vitro validation of the 8oxodG
ELISA

Amount of +8oxodG DNA

Amount of -8oxodG DNA

Total amount of

per well (ng)

per well (ng)

DNA per well (ng)

0

100

100

6.25

93.75

100

12.5

87.5

100

25

75

100

50

50

100

100

100

100

Note. An increasing amount of+8oxoG DNA was loaded in triplicate wells of the
8oxodG ELISA plate. The -8oxodG DNA was added to these wells such that the total
amount of DNA in each well was 100 ng. The DNA was then subjected to the 8oxodG
ELISA and the concentration of 8oxodG lesions in each well was determined.

59

18.0 -

Concentrat on of 8oxodG lesic
(ng/ml)

?

16.0 -

±

14.0 -

R2 = 0.9972

y f

12.0 10.0
8.0 •
6.0

s

4.0 2.0 A

n
0.0

0.5

1.0

1.5

2.0

2.5

log amount of target DNA (ng)

Figure 12. Dose-dependent detection of 8oxodG lesions on the +8oxodG DNA in the
presence of the -8oxodG DNA. The -8oxodG was spiked with an increasing amount of
+8oxodG (target) DNA so that the final amount of DNA in each well was 100 ng. The
8oxodG lesions were detected and quantified using the HT 8oxodG ELISA Kit as
described in the Methods section. The data points represent the mean concentration of
8oxodG lesions. The vertical lines represent the standard deviation.

Titration of the Amount ofStreptavidin-Coated Magnetic Beads to Use in the BER Assay
In the BER assay, following lysis of the cells transfected with the biotin-tagged
substrate or control DNA, the transfected DNA will have to be captured using
streptavidin-coated magnetic beads. In order to determine the optimal amount of beads
required to effectively capture the transfected substrate or control DNA following cell
lysis, a titration using different bead concentrations was performed.
Double-stranded control (-8oxodG/biotinylated) DNA (100 ng), and different
amounts of beads (10 u.g, 50 ug, 100 ug, 150 ug) were used for the titration. Following
binding of the control DNA to the beads, the DNA was denatured using 0.1 M sodium
hydroxide, and the supernatant was collected in the presence of a magnet. This step
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would, in theory, isolate the -8oxodG DNA strand from the biotinylated DNA strand
bound to the beads. The DNA isolated from each of the four experiments that used
different amounts of beads were then analyzed on a denaturing gel (Figure 13 A) after
staining with SYBR® Green II.
The intensity of the 24-mer DNA bands obtained for the DNA isolated from each
of the four experiments, and the reference DNA band (11 ng of-8oxodG DNA strand)
were determined using the Image J software (Figure 13B). The band intensities of the
samples were then expressed as a percentage of the band intensity of the reference DNA.
Since the amount of DNA in the reference band was known (11 ng), the amount of DNA
in each band from the sample lanes (lanes 3-6) was estimated. Using these data, the total
amount of DNA isolated from each of the four bead capture experiments was estimated
(Figure 13B).
The expected amount of isolated single-stranded -8oxodG DNA from 100 ng of
double-stranded control DNA, following denaturation, was 50 ng. Approximately
13.98 ng, 20.41 ng, 41.66 ng and 52.05 ng of single-stranded control DNA was isolated
from 10 ng, 50 ug, 100 ug, and 150 ug of bead-DNA suspension respectively, following
denaturation. From the titration performed, 150 ug of streptavidin-coated magnetic beads
was determined to be the optimal amount of beads that could bind 100 ng of substrate or
control DNA. Thus, the optimal ratio of the amount of substrate or control DNA to the
amount of streptavidin-coated beads to be used was estimated to be approximately 1 ng
DNA to 1.5 ug beads.
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A.
Lanes

-SoxodG DNA
strands

art* i f f
B.

DNA isolated following titration of
streptavidin-coated magnetic beads
Reference Band
Band Intensity

2078

10 jxg

50 ng

100 [xg

150 [xg

528

771

1574

1966

Relative band intensity

1

0.254

0.371

0.757

0.946

Amount of DNA per

11

2.795

4.081

8.332

.10.407

13.98

20.41

41.66

52.05

band (ng/5[xl)
Amount of DNA in the
supernatant (ng/25u.l)

Figure 13. Titration of the amount of streptavidin-coated magnetic beads required to
capture the control DNA. The control DNA (100 ng) was mixed with streptavidin-coated
magnetic beads (10 [xg, 50 jxg, 100 u.g, 150 [xg) and incubated as described in the
Methods section. The DNA captured by the beads was then denatured using
0.1 M sodium hydroxide in the presence of a magnet, and the DNA in the supernatant
was isolated. The isolated DNA was analyzed on a 12% TBE-polyacrylamide 8.3 M urea
gel (A) following denaturation by heating at 90 °C in 95% (vol/vol) formamide. Lane 1:
10 bp DNA ladder; lane 2: Reference band (-8oxodG DNA strand); lane 3, 4, 5, 6: DNA
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isolated following capture and denaturation of control DNA using 10 ug, 50 (ig, 100 \xg,
and 150 \xg beads respectively. The band intensities were determined using Image J
software (B) and the amount of DNA in each band and in the eluted supernatant was
calculated from the known amount of DNA in the reference band.
The gel (Figure 13 A) also showed that only the -8oxodG DNA strand (24-mer)
and not the biotinylated DNA strand (28-mer) was isolated following bead capture and
denaturation. Thus, treatment with 0.1 M sodium hydroxide did not disrupt the
streptavidin-biotin linkages. As seen in Figure 8, an additional band (~40-mer) was seen
in all the lanes. As mentioned before, it is believed that this band is due to self-annealing
of the -8oxodG DNA strands.

Selection of a Suitable Fluorescent Dye for the Quantification of the Isolated DNA in the
BER assay
In the BER assay, following capture and denaturation of the transfected substrate
DNA, the isolated DNA containing the +8oxodG DNA strand will have to be quantified
prior to being used in the 8oxodG ELISA. Two fluorescent dyes (SYBR® Green II and
Quant-iT™ Oligreen) were evaluated for their efficiency in quantifying single-stranded
DNA. The single-stranded -8oxodG DNA was used to generate standards ranging from
0-50 ng/ml (in 10 ng/ml increments). The R2 values of the standard curve generated
using the same set of standards and measured using each of the two dyes were then
compared. The Quant-iT™ Oligreen dye gave better R2 value for the standard curve
(R2 = 0.9982) when compared to the SYBR® Green II dye (R2 = 0.8877). Similar results
were obtained when using standards ranging from 0-25 ng/ml (in 5 ng/ml increments);
the R2 value for the standard curve using Quant-iT™ Oligreen dye and SYBR® Green II

63

dye was 0.9969 and 0.7291 respectively. Thus, the Quant-iT™ Oligreen fluorescent dye
was chosen for the quantification of the isolated DNA following denaturation in the BER
assay.

Transfection of the Substrate or Control DNA into Target Cells
The first step of the BER assay involves the transfection of the substrate DNA
into target cells. Since the assay was being developed to confirm the results observed
from the first part of our study (described in chapter one), we used SUM149PT cells to
determine conditions for substrate or control DNA transfection. Double-stranded control
DNA (-8oxodG/biotinylated DNA) was used in the optimization experiments.
Two different transfection reagents (Lipofectamine™ 2000 and
Oligofectamine™) were first compared for their efficiency in transfection of the control
DNA into the target cells. No cytotoxicity was observed among the untransfected cells
that were treated only with either of the two reagents (2 ul of reagent per well of a
24-well plate). Since transfection of biotin-tagged oligonucleotides has not been
reported previously, we decided to use a large amount of control DNA for the
transfection to first verify if the biotin-tagged DNA can successfully transfect cells. Thus
800 ng of control DNA was transfected using either of the two reagents (2 ul of reagent
per well) into SUM149PT cells. Following 4 hr of incubation, the cells were lysed. To
prevent the denaturation of the biotin moiety in the control DNA, a nonionic
detergent-based cell lysis buffer was used. Since the optimal ratio of the amount of
substrate or control DNA to the amount of streptavidin-coated beads was previously
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determined to be 1 ng DNA to 1.5 fag beads (Figure 13), 850 |j.g of beads were used to
capture the control DNA (800 ng) from the cell lysate. The captured DNA was then
denatured in the presence of a magnet, and the DNA recovered in the supernatant was
quantified using the Quant-iT™ Oligreen dye. The concentration of DNA in the eluted
supernatant was approximately the same for cells transfected with Lipofectamine™ 2000
(0.27 ng/ul) and Oligofectamine™ reagent (0.25 ng/|al) (Figure 14). Since
Lipofectamine™ 2000 is a more commonly used reagent, we decided to use this for
future experiments.
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Figure 14. Selection of a suitable transfection reagent for the BER assay. SUM149PT
cells were transfected with the control DNA (800 ng) using 2 p.l/well of either the
Lipofectamine™ 2000 or Oligofectamine™ transfection reagent. The cell lysis, capture
and denaturation steps were performed as described in the Methods section. The DNA
recovered in the supernatant following denaturation, was quantified using the Quant-iT™
Oligreen dye. The bars represent the mean concentrations of DNA recovered from two
independent experiments. The vertical lines represent standard errors of the means.
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Following selection of a suitable transfection reagent, the optimal volume of the
reagent to use for transfection was then determined. Out of three different volumes of
Lipofectamine™ 2000 tested (2, 4, or 6 ul of reagent per well of a 24-well plate), the
concentration of the recovered DNA was the highest when 2 ul of Lipofectamine™ 2000
was used for transfection of SUM149PT cells (Figure 15). No cytotoxicity was observed
in the transfected cells (with 800 ng control DNA) or untransfected cell controls (treated
only with 2, 4, or 6 ul of Lipofectamine™ 2000), following incubation for 4 hr at 37 °C.
This shows that neither the reagent, nor the combination of reagent with DNA were
cytotoxic to the cells at the concentrations used and the time incubated.
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Figure 15. Optimal volume of Lipofectamine™ 2000 for use in the transfection step of
the BER assay. The SUM149PT cells were transfected with control DNA (800 ng) using
either 2 ul, 4 ul or 6 ul of Lipofectamine™ 2000. The cell lysis, capture and
denaturation steps were performed as described in the Methods section. The DNA eluted
in the supernatant following denaturation was quantified using the Quant-iT™ Oligreen
dye. LF = Lipofectamine™ 2000.
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Gel Analysis of the DNA Recoveredfollowing Transfection of Substrate or Control DNA
into SUM149PTandMCF7 Cells
Following transfection of substrate DNA (+8oxodG/biotinylated DNA) into target
cells, incubation, cell lysis, bead capture and denaturation in the presence of a magnet,
the recovered DNA should only consist of the +8oxodG DNA strand (Figure 7). To
confirm that the DNA recovered following transfection of the substrate DNA into
SUM149PT cells consisted only of the +8oxodG DNA strands, the transfection was
performed in SUM149PT cells using substrate DNA (800 ng) and Lipofectamine™ 2000.
In addition, another batch of SUM149PT cells was transfected with the control DNA
(800 ng) instead of the substrate DNA. Following incubation for 4 hr, and cell lysis, the
transfected substrate and control DNA were captured, denatured, and the supernatant was
collected in the presence of a magnet. Equal volumes of the supernatant from each
transfection were electrophoresed on a denaturing gel (Figure 16A, lanes 2, 3). The gel
showed one band that corresponds to the 28-mer biotinylated DNA and another band that
corresponds to the 24-mer +8oxodG or -8oxodG DNA. Both the bands were observed in
the DNA recovered following transfection of the control DNA (Fig 16A, lane 2) and the
substrate DNA (Fig 16A, lane 3) into SUM149PT cells. In addition to these two bands, a
third band, approximately 50 bases in length, was seen only in the DNA recovered
following transfection of the control DNA (Fig 16 A, lane 2). We speculated that this
50-mer was formed due to self-annealing of the -8oxodG DNA strands, as was previously
observed on gel electrophoresis of single-stranded -8oxodG DNA (Figure 8). The
absence of this 50-mer band in the DNA recovered following transfection of the substrate
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DNA (Fig 16A, lane 3) is also consistent with the observations from electrophoresis of
the single-stranded +8oxodG DNA in Figure 8.
The substrate and control DNA were also transfected into another cell line
(MCF7), to show that the bands observed were not cell-type specific and to also
demonstrate that the substrate or control DNA could be transfected into other cell lines.
Following gel electrophoresis, the DNA recovered following transfection of the control
DNA (Figure 16A, lane 4) and the substrate DNA (Figure 16A, lane 5) into MCF7 cells
produced bands identical to those observed from the transfections in the SUM149PT cells
(Figure 16A, lanes 2, 3).
To further confirm that the DNA bands observed in Figure 16A were specific for
the transfected DNA, we prepared two sets of untransfected SUM149PT cells. Both sets
of cells were lysed. The lysate from one set of cells, on electrophoresis, showed a smear
of DNA (Figure 16B, lane 2). No bands corresponding to the substrate or control DNA
(24, 28 bases) were seen. The lysate from the other set of untransfected SUM149PT cells
was subjected to bead capture and denaturation. On electrophoresis of the denatured
supernatant, no bands were observed (Figure 16B, lane 3). Nanodrop spectrophotometry
of this denatured supernatant also confirmed the absence of DNA (data not shown). This
suggested that no DNA was isolated on subjecting the untransfected SUM149PT cells to
lysis, bead capture and denaturation. Taken together with the data obtained in Figure
16A, we concluded that the DNA recovered from the cell lysates of SUM149PT and
MCF7 cells transfected with the substrate and control DNA consisted only of the
transfected DNA.
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Figure 16. Transfection of control and substrate DNA into SUM149PT and MCF7 cells.
SUM149PT and MCF7 cells were transfected with the control or substrate DNA (800 ng)
using Lipofectamine™ 2000 (A). The cell lysis, capture and denaturation steps were
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performed as described in the Methods section. The DNA eluted in the supernatant was
run on a 12% polyacrylamide 8.3 M urea gel. Lane 1: 10 bp DNA ladder; lanes 2, 3:
DNA recovered following transfection of SUM149PT cells with control DNA and
substrate DNA respectively; lanes 4, 5: DNA recovered following transfection of MCF7
cells with control DNA and substrate DNA respectively. Cell lysates from untransfected
SUM149PT cells (B) were either used as is (Panel B, lane 2), or subjected to bead capture
and denaturation (Panel B, lane 3), prior to being electrophoresed. A 10 bp DNA ladder
(Panel B, lane 1) is also shown.

Consequences of the Coelution of the Biotinylated DNA Strand with the +8oxodG or
SoxodG DNA strand following Denaturation of Captured Substrate or Control DNA
Figure 16A showed that the +8oxodG or -8oxodG DNA strand (24-mer) and the
biotinylated DNA strand (28-mer) were present in the supernatant following bead capture
of transfected DNA and denaturation. The presence of the biotinylated DNA strand in
the supernatant was unexpected since we had previously observed that when using
similar bead capture and denaturation conditions, the biotinylated strand did not coelute
with the +8oxodG or -8oxodG DNA strand (Figure 13). Figure 16A also showed that the
amount of biotinylated DNA that coeluted with the +8oxodG or -8oxodG DNA strands in
each of the four transfection experiments (Figure 16A, lanes 2-5) was consistent (as
visualized by the band intensity). This suggested that as long as the DNA capture,
denaturation and recovery steps are consistently performed following every transfection
experiment, the percentage of coeluted biotinylated DNA (if any) that is recovered from
every experiment would be similar. Thus, if the presence of the biotinylated DNA did
not compromise the efficiency of the 8oxodG ELISA to quantify lesions on the +8oxodG
DNA, its coelution may be overlooked. To verify this, the ability of the ELISA to detect
and quantify 8oxodG lesions on increasing amounts of+8xodG DNA, in the
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absence/presence of an equal amount of the biotinylated DNA was monitored (Table 3,
Figure 17).

Table 3
Amount of biotinylated DNA and/or +8oxodG DNA used to determine the efficiency of
the 8oxodG ELISA
A.

B.

Amount of+8oxodG

Amount of+8oxodG

Amount of biotinylated

DNA per well (ng)

DNA per well (ng)

DNA per well (ng)

0

0

0

6.25

6.25

6.25

12.5

12.5

12.5

25

25

25

50

50

50

100

100

100

Note. An increasing amount of+8oxodG DNA was loaded in triplicate wells of the
8oxodG ELISA plate (A). An increasing amount of+8oxodG DNA spiked with an equal
amount of biotinylated DNA was also loaded in triplicate wells of the 8oxodG ELISA
plate (B). The DNA was then subjected to the 8oxodG ELISA and the concentration of
8oxodG lesions in each well was determined.
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Figure 17. Quantification of 8oxodG lesions on the +8oxodG DNA in the presence or
absence of the biotinylated DNA. Increasing amounts of +8oxodG (target) DNA strand
were subjected to the 8oxodG ELISA with or without equal amounts of biotinylated
DNA strand. The concentration of 8oxodG lesions on the +8oxodG DNA strand in the
absence (black diamonds, black trendline) or presence (red squares, red trendline) of the
biotinylated DNA strand was then determined.

The slopes of the trend lines (Figure 17) obtained for the concentration of 8oxodG
lesions on increasing amounts of +8oxodG DNA were similar in both the absence
(slope = 0.186) and presence (slope = 0.181) of biotinylated DNA. Thus, the presence of
the biotinylated DNA does not interfere with the quantification of 8oxodG lesions on the
+8oxodG DNA strand and hence its coelution following capture and denaturation of the
substrate DNA may be overlooked.
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Discussion

Defects in the BER of 8oxodG lesions have been implicated in cancer (Paz-Elizur
et al., 2003). The efficiency of BER of 8oxodG lesions in mammalian cells may be
determined by monitoring the disappearance of 8oxodG levels in cellular DNA,
following treatment with oxidizing agents. Techniques such as comet assays,
immunoassays and HPLC-ECD that have been developed for this purpose suffer from
issues related to their sensitivity, specificity and artifact production. Besides the HCR
assay, currently, no other reliable assay to measure in vivo BER of 8oxodG lesions using
DNA repair substrates is available. Thus, in this study, we have designed a novel in vivo
assay for measuring BER of 8oxodG lesions using an oligonucleotide DNA substrate.
This assay provides an advantage over the HCR assay because it detects the kinetics of
BER, whereas the HCR assay is an end-point assay.
The double-stranded oligonucleotide DNA substrate used in our BER assay
consists of an 8oxodG lesion on one strand and a 3' biotin tag on the complementary
strand. The substrate DNA is transfected into target cells using Lipofectamine™ 2000
and incubated for an increasing period of time to allow for repair. The cells are then
lysed using a nonionic cell lysis buffer and the lysate is treated with streptavidin-coated
magnetic beads (DNA [ng]: bead [ug] ratio = 1:1.5), to allow the biotin-tagged substrate
DNA to be captured from the cell lysate. Following DNA capture and washing to
remove nonspecific DNA binding to the beads, the bead bound DNA is treated with
0.1 M sodium hydroxide to denature the untagged target strand from the biotin-tagged
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nontarget strand (still bound to the beads). In the presence of a magnet, the bead bound
nontarget strand is separated from the denatured target strands (in the supernatant). The
DNA in the supernatant is then quantified by fluorimetry using the Quant-iT™ Oligreen
fluorescent dye. Equal amounts of DNA from each time-point (the various time-points at
which the target cells were incubated) are then subjected to an 8oxodG competitive
ELISA, to quantify the amount of 8oxodG lesions on the target DNA. In vivo BER is
measured as the disappearance of 8oxodG lesions with time.
The substrate DNA is a critical component of any repair assay. Thus, we first
generated a list of specifications for selection of a suitable substrate DNA for our assay.
Being an in vivo assay, the substrate DNA has to be transfected into cells. Thus, the
substrate DNA should be double-stranded, with one or more 8oxodG lesions at
predetermined position(s). It should also be easy to transfect into cells and be stable in
vivo. Since the recognition of the lesions by hOGGl followed by hOGGl- or
APE 1-mediated cleavage is a critical step in BER, the biochemistry of the substrate DNA
chosen should not interfere with these steps. Following cell lysis, the DNA should be
easily captured and purified, and form well characterized bands after gel electrophoresis.
As a first step, to make the choice between plasmid and linear oligonucleotide
substrates, the advantages and disadvantages of each substrate in relevance to this assay
were analyzed. Plasmid substrates can be transfected using common lipid-based reagents
and are stable in vivo. In addition, plasmid substrates allow analysis of the long-patch
BER (LP-BER) of base lesions, because the clamp protein proliferating cell-nuclear
antigen (PCNA) required for LP-BER, functions only on circular DNA substrates (Biade,
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Sobol, Wilson, & Matsumoto, 1998). On the other hand, the preparation and purification
of plasmid DNA substrates containing 8oxodG lesions at predetermined positions
(described by Hou, Prasad, Asagoshi, Masaoka & Wilson, 2007) is tedious. In addition,
genomic DNA contamination may be introduced during the isolation of the plasmids
from the cell lysate, following transfection and incubation in target cells.
Linear oligonucleotide DNA substrates on the other hand can be annealed from
single-stranded commercially synthesized and purified strands. If tagged, the
oligonucleotide DNA substrate can be easily captured and purified following cell lysis,
without disrupting the 8oxodG lesions. However, the disadvantages of these substrates
are that they do not allow repair using the LP-BER pathway, and their stability may be
compromised in vivo. Studies conducted in vitro have shown that hOGGl-mediated
repair of 8oxodG occurs almost exclusively along the short- patch BER (SP-BER)
pathway (Dianov et. al., 1998; Fortini et. al., 2003). Thus, the use of a linear
oligonucleotide DNA substrate to measure BER of 8oxodG lesions should not pose a
problem. In addition, partially phosphorothionated substrate DNA may be used to
maintain in vivo substrate stability. Thus, we decided to use a linear oligonucleotide
DNA substrate for our BER assay.
The successful hOGGl-mediated incision of a commercially available (Trevigen)
oligonucleotide, 24 bases in length, carrying a single 8oxodG lesion, has been shown
before (Achanta & Huang, 2004). The study also used a 3' biotin tagged oligonucleotide
that was complementary to the 8oxodG containing strand. Thus, the two oligonucleotides
described by Achanta and Huang (2004), were chosen for our assay. To prevent

75

interference with enzyme binding and excision of the 8oxodG lesion on the target strand,
the biotin moiety was tagged only to the complementary strand.
Denaturing gel electrophoresis of the purchased single stranded DNA
oligonucleotides revealed bands of the expected sizes for the single-stranded +8oxodG
DNA and biotinylated DNA (Figure 8). However, for the single-stranded -8oxodG DNA,
besides a 24 base fragment, another fragment which was approximately 50 bases in
length was observed. Although the +8oxodG DNA had the same sequence as the
-8oxodG DNA plus an 8oxodG lesion, the 50-mer DNA band was not observed in the
+8oxodG DNA lane. We speculated that this additional band was formed due to
self-annealing of the -8oxodG DNA strands, and that this was not seen with the +8oxodG
DNA strands because the 8oxodG lesion destabilized and thus prevented self-annealing.
To test this hypothesis, we treated the -8oxodG DNA with higher formamide
concentrations (98-100% [vol/vol]) to completely disrupt self-annealing, and
electrophoresed the DNA in a denaturing gel. Following staining, the additional 50 base
length band was not observed (data not shown). However, when this experiment was
repeated, the band reappeared (data not shown). In the future, the identity of the
fragment may be confirmed by excision of the band, elution of the DNA and sequencing.
Transfection of deoxyribonucleotides into cell cultures has been previously
performed (Li, Dowbenko, & Lasky, 2002). However, no study to date has transfected
biotin-tagged oligonucleotides into cell cultures. Thus, we first had to verify if the
biotin-tagged substrate DNA could successfully be transfected into target cells. The
double-stranded control DNA was used to optimize conditions for transfection because it
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was identical to the substrate DNA, except for the absence of an 8oxodG lesion. The
control DNA was transfected into SUM149PT cells using two different lipid-based
transfectants. At the end of cell lysis, capture of the transfected DNA, and denaturation,
the supernatant was collected and subjected to DNA quantification by fluorimetry. The
analysis showed the presence of DNA in the supernatant (Figure 14). However, the
species of DNA in the supernatant could not be verified by gel electrophoresis because
the amount of DNA recovered was low. The transfection was then repeated in
SUM149PT cells (with both control and substrate DNA), and this time the entire volume
of supernatant isolated following bead capture of the lysate and denaturation was
electrophoresed on a denaturing gel, to visualize the DNA recovered. The gel showed the
presence of the DNA bands that corresponded to those of the substrate and control DNA
(Figure 16A). The same results were obtained when the experiment was repeated using
another cell line (MCF7). The use of two untransfected SUM149PT cell controls
confirmed that the DNA bands observed were not endogenous to the cell lysate (Figure
16B). Taken together, these results confirmed that the biotin-tagged substrate and control
DNA could indeed be transfected into cell cultures.
Although we did observe transfection of the substrate and control DNA, the
percentage of transfected DNA recovered following cell lysis, capture and denaturation
was low (-2.03%). This may be due to a number of reasons; failure of the
oligonucleotide DNA substrate to enter the cells, their susceptibility to cytoplasmic,
lysosomal, or other organellar DNases, the exocytosis of the DNA, or the loss of DNA
during cell division (Lechardeur et al., 1999). To circumvent digestion by cellular
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endo- and exonucleases, some of the phosphate groups in the oligonucleotide substrate
may be modified by phosphorothioation in future experiments. It is however important
not to modify phosphates that flank the 8oxodG lesion, so that the hOGGl- or
APE 1 -mediated strand cleavage and other BER steps may proceed unhindered. It may
also be useful to optimize the volume of cell lysis buffer used to lyse the cells following
transfection, to ensure the release of transfected DNA from all the cells. It has been
shown with plasmid DNA that the use of peptide scaffolds containing cationic peptides
(which bind to the DNA) conjugated to a nonclassical nuclear localization sequence
(NLS), greatly improves nuclear import and transfection efficiency (Subramanian,
Ranganathan, & Diamond, 1999). These peptide scaffolds are commercially available as
the reagent Nupherin™ (Biomol). In the future, the ability of this reagent to improve
transfection of the substrate DNA, and to specifically target the DNA to the nucleus to
monitor nuclear BER, may be investigated.
An unexpected observation from the transfection of control and substrate DNA
was the coelution of the biotinylated DNA strand with the +8oxodG or -8oxodG DNA
strand, following capture and denaturation (Figure 16A). This was however not observed
during preliminary analysis of the bead capture and denaturation steps using the control
DNA (Figure 13). We speculate that this may be due to the partial denaturation of the
biotin moiety during repeated freeze-thaw of the control and substrate DNA for use in the
optimization experiments. This may compromise the ability of the biotin-tagged
substrate to bind strongly to the streptavidin-coated beads, thereby resulting in its elution
following treatment with 0.1 M sodium hydroxide. If this were the case, then some of the
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biotin-tagged substrate may have also been lost during the wash steps, which would then
account for the low percentage recovery of the transfected DNA. This may be verified by
analysis of the supernatant from the wash steps. In the future, aliquots of the substrate
DNA may be prepared following quantification, to prevent the denaturation of the biotin
moiety due to repeated freeze-thaw. It may also be useful to optimize the volume and
concentration of sodium hydroxide, and the incubation time for the denaturation step, to
ensure that the coelution of the biotinylated DNA strand was not due to the conditions
used for these steps.
A commercially available competitive ELISA kit (Trevigen) was evaluated in this
study for its specificity and efficiency in the detection of 8oxodG lesions on the +8oxodG
DNA. The +8oxodG and -8oxodG DNA were used for this evaluation. The absorbance
at 450 nm for the -8oxodG DNA was consistently at or near the readings obtained for the
blank (0 ng/ml standard), while the readings for the +8oxodG DNA were lesser than the
blank (lesser absorbance corresponds to more 8oxodG in competitive ELISA). This
showed that the antibody specifically interacts with 8oxodG lesions. To determine
conditions that improved specificity, the ELISA was performed using different blocking
agents, primary antibody dilutions, and primary antibody incubation temperatures. It was
observed that blocking the wells with 2% FBS gave high specificity when compared to
10% FBS and 1% BSA. The specificity was also highest when incubating the +8oxodG
or -8oxodG DNA in the wells at room temperature, with a 1/250 dilution of the primary
antibody. The ELISA detected 8oxodG lesions on the +8oxodG DNA with an efficiency
of 46.3% and also demonstrated the ability to detect the lesions on the +8oxodG DNA in
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a dose-dependent manner, in the presence of the -8oxodG DNA. Thus, when used in the
BER assay, the 8oxodG ELISA would effectively quantify lesions on the unrepaired
target DNA in the presence of repaired target DNA. Thus, the competitive 8oxodG
ELISA (Trevigen) with some modifications, was found to be suitable for use in our assay
to specifically detect and quantify 8oxodG lesions on the +8oxodG DNA of the
oligonucleotide DNA substrate.
In summary, the design of a novel assay to measure the in vivo BER of 8oxodG
lesions on an oligonucleotide DNA substrate was outlined in this study. The preparation
of the substrate DNA and the optimal working conditions for the competitive ELISA
were established. Preliminary experiments confirmed that the biotin-tagged substrate
DNA can be successfully transfected into target cell cultures, and can be captured and
purified using streptavidin-coated magnetic beads. By incubating cell cultures with the
transfected substrate DNA for an increasing period of time, the steady-state
measurements of BER activity in the cell may be obtained. In the future, the assay will
have to be validated in vivo by comparing repair of the oligonucleotide DNA substrate in
cell cultures that are known to possess functional BER versus those that do not. Since
hOGGl is a critical enzyme involved in the repair of 8oxodG lesions, an isogenic system
consisting of hOGGl knockout and hOGGl wild-type cells may be used for validating
the assay. To this end, stable isogenic cell lines for hOGGl knockdown derived from
MCF7 parental cell lines, have been developed at the Ford laboratory, and will be used to
validate this assay in the future. Once validated, the assay may be used to confirm the
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role of the BRCA1 protein, and investigate the role of other potential cancer-related
proteins in the BER pathway.
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CONCLUSION

The 8oxodG lesions are some of the most frequently observed products of
oxidative DNA damage in cells. Unless repaired by the BER pathway, these lesions
could result in AP sites, strand breaks, genetic instability, and carcinogenesis. Defects in
BER may occur due to germ-line or somatic mutations in the genes coding for
BER-associated proteins. Defective cellular BER may be detected using assays, most of
which are performed in vitro using cell protein extracts and radiolabeled reagents. A
novel in vivo HCR assay for BER was recently developed in our laboratory. In chapter
one of this thesis, we described the use of the HCR assay in SUM149PT cells to
investigate the role of the BRCA1 protein in BER. An approximately two-fold increase
in BER levels in cells transfected with the jBi?G47-wild type construct when compared to
those transfected with the empty vector control was observed. This suggested that the
BRCA1 protein was involved in the BER pathway.
In order to corroborate the findings from chapter one, another in vivo assay for
BER was necessary. In chapter two of this thesis, we described our design and
optimization of a novel in vivo assay for BER. This assay monitors BER in target cells
using a biotin-tagged, double-stranded, 8oxodG containing oligonucleotide DNA
substrate, and an 8oxodG ELISA. Our assay offers an advantage over existing assays in
that it measures the kinetics of BER in vivo and it does not use radiolabeled reagents. In
the future, following validation of this assay in vivo, it may be used to confirm the role of
the BRCA1 protein in BER.
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